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1. Preface 
 Reduced propionates and deoxypropionates are the fundamental backbones 
of several important natural products. Because every carbon in a propionate 
is a potential candidate for a chiral center, it is imperative to control both the 
relative and the absolute stereochemistry. Several methods for the synthesis 
of deoxypropionates and reduced propionates have already been reported. 
However, with the ever increasing volume of complexity of natural products 
and their structures, new methods for synthesis are required. 
 The title of this dissertation is the use of benzimidazoles as protonating 
agents and their application to the total synthesis of natural products.  
 In the first chapter, a general introduction into reduced propionates and 
deoxypropionates has been provided. Commonly used protocols for the 
synthesis of the same are also discussed.  
 In the second chapter, Birch reductions with various protonating agents are 
discussed. The change in diastereomeric ratio with the change in chiral 
auxiliaries has also been examined. Its application to the synthesis of the sex 
pheromone of Macrocentrus grandii was then discussed. 
 In the third chapter, an isomerization reaction is examined along with its 
result with the change observed with varying chiral auxiliaries. A formal 
synthesis of seragamide A is also discussed.  
 In the fourth chapter, a total synthesis of PF1163B has been achieved. 
PF1163B is a cyclodepsipeptide that has potent antibiotic activities. Its 
complex structure and useful bioactivity makes it a desired target molecule.  
 In the fifth chapter, a synthetic study on spongidepsin is discussed. 
Spongidepsin is also a cyclodepsipeptide with a potent anti-tumor activity.  
 In the sixth chapter, a conclusion to the thesis is provided. 
 In the seventh chapter, all experimental details including spectroscopic data 
of all compounds have been provided. 
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2. Abbreviations 
AIBN: Azobisisobutyronitrile 
BOPCl: Bis (2-oxo -3-oxazolidinyl)phosphinic chloride 
CSA: Camphorsulfonic acid 
DCC: N,N’-Dicyclohexylcarbodiimide 
DCM: Dichloromethane 
DIBAL: Diisobutylaluminium hydride 
DIPEA: Diisopropylethylamine 
DMAP: Dimethylaminopyridine 
DMF: N,N- Dimethylformamide 
EDCI: N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide 
LAH: Lithium Aluminium hydride 
NaHMDS: Sodium Hexamethyldisilylamide 
p-TsOH : p-Toluenesulfonic acid 
TBS: tert-butyldimethylsilyl 
TBTH: Tributyltinhydride 
TEA: Triethylamine 
TFA: Trifluoroacetic acid 
THF: Tetrahydrofuran 
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Chapter 1: Introduction 
1.1  General introduction to reduced propionates and deoxypropionates 
 Reduced propionates and deoxypropionates are ubiquitous and constitute the 
skeletal backbone of several important natural products. The complex natural 
products containing a reduced propionate or a deoxypropionate may range 
from secondary metabolites to simple lactones derived from insects, fungi or 
algae.1 While polyketides impart to living organisms a chemical defense, 
their exact role, however, remains unsolved.2 Structurally, deoxypropionates 
and reduced propionates have the following skeletal structure (Fig 1). 
              
 Modifications to the structural motifs of the propionates can lead to further 
complex and diverse structures. It is perhaps then not a surprise that 
propionates, along with their structural modifications, are used in medicinal 
chemistry. Pthiocerol dimycoserosate A (PDIM A, 3, Fig. 2)3-6 is able to 
induce an immune response from the host and can increase the cell wall 
strength of bacteria.3 
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 (+)-Siphonarienal (4, Fig 2) is another example of a deoxypropionate that 
was isolated from the gastropod mollusks of the genus Siphonaria found in 
the Mediterranean and Atlantic oceans and shows antimicrobial activity. 7,8 
Borrelidin (5, Fig 2) is an unwonted example of a polyketide that exhibits 
cytotoxicity comprising both a trans and a cis double bond geometry – 
confirmed by both total synthesis9-11 and X-ray diffraction studies.12 The 
geometry of the double bonds have garnered much attention from the 
scientific community as normally, during the biosynthesis, trans double 
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bonds are generated from syn dehydration of alcohols13,14, while cis geometry 
results from the action of external enzymes.15-17 
 As our efficiency to fight bacteria is in a downward spiral because of the 
emergence of antibiotic resistant bacteria, the need of the hour is the isolation, 
characterization and synthesis of new antibiotics to combat the second 
generation of drug-resistant pathogens.18 For this purpose, the generation of a 
new class of polyketides in modern medicine is required.19 Aromatic 
polyketides or polypropionates have also recently carved out a niche for 
themselves for being both anticancer agents such as doxorubicin or 
antibiotics tetracyclines. 20 
1.2  Iterative methodology for the synthesis of polyketides 
 Since the absolute stereochemistry of the reduced propionate and the 
polyketides are of primary importance, several synthetic chemists have found 
various methods for the synthesis of one stereochemistry of a chiral carbon 
over the other. A very common approach to the synthesis of polyketides is an 
iterative method. 21,22 In 2005, Minnard et al. reported an iterative route to 
obtain enantiomerically pure deoxypropionate subunits (Scheme 1.1) and 
applied the said method for the synthesis of the polyketide lardolure (14, 
Scheme 1.2).23 
 
 As shown in Scheme 1.1, a conjugate addition to α,β-unsaturated thioesters 
required the use of a chiral ligand such as (R)-1-[(SP)-2-
(diphenylphosphino)ferrocenyl]ethyldicyclohexylphosphine. Compound 6 is 
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an α,β-unsaturated thioester which under the conjugate addition reaction with 
the aforesaid chiral catalyst provided the new chiral center in R-configuration 
to give reduced 7. Reduction of the thioester in the presence of palladium 
catalyst and a Wittig olefination regenerated the α,β-unsaturated thioester 9. 
An iterative conjugate addition reaction along the same procedure provided 
the two syn-methyl groups. On optimizing this reaction, Minnard et al. set 
about the total synthesis of (˗)-lardolure (14) using the same protocol. 
  
 
 From an enantiomerically pure 11, reduction with palladium and a Wittig 
olefination furnished the α,β-unsaturated thioester 12 (Scheme 1.2). Iterative 
reactions including conjugate addition reaction, palladium catalyzed 
reduction and Wittig olefination provided 13 which was converted to 
lardolure (14) in four further steps. Hence, iterative methods have found their 
importance in the total synthesis of natural products. 
 However, iterative methods have certain drawbacks. The routes are generally 
longer and thus require more time for the synthesis of important natural 
products. 
 
 
 
 
7 
 
 1.3 Transition metal catalyzed methodology for the synthesis of 
polyketides 
 As an alternative to the iterative route, another commonly used pathway for 
the synthesis of reduced propionates is via one-pot transition metal 
catalysis.24-28  
 In 2007, Burgess et al. designed the synthesis of (S,R,R,S,R,S)-
4,6,8,10,16,18-hexamethyldocosane (15), a hydrocarbon isolated from female 
Australian melolonthine beetles.29 
 
 
 The synthesis of the deoxypropionate (15) involved the usage of iridium 
catalyzed hydrogenation reactions to provide the chiral centers 
stereoselectively (Scheme 1.3). Stereoselective hydrogenation of the Z-allylic 
alcohol 16 in the presence of iridium catalyst provided the reduced 17 in a 
diastereomeric ratio of 34:1. Compound 17 was then converted to the eastern 
fragment 18 in 6 steps. 
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 The western fragment of (S,R,R,S,R,S)-4,6,8,10,16,18-hexamethyldocosane 
was synthesized similarly using the asymmetric hydrogenation reaction as the 
crucial step (Scheme 1.4). The alcohol 19 was first converted into the α,β-
unsaturated ester 20 following which the unsaturation was reduced under 
hydrogen using iridium catalyst to provide the reduced ester 21 in high 
diastereoselectivity. In 5 more steps, the western segment of (S,R,R,S,R,S)-
4,6,8,10,16,18-hexamethyldocosane 22 was synthesized.  
           
 
 Fusion of the western and the eastern fragment was carried out under 
Horner-Wadsworth-Emmons conditions (Scheme 1.5).30 The olefin was 
reduced in the presence of palladium followed by a modified Wolff-Kischner 
reduction31,32 to remove the ketone provided the hydrocarbon 15. 
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1.4 Enolate protonation methodology for the synthesis of polyketides 
 In Scheme 1.6, a pictorial representation of the protonation of enolates has 
been provided. As the enolate is provided a proton by a protonating agent, 
there is the formation of a chiral carbon. If somehow, certain factors such as 
temperature, substrate scope, size of the protonating agent or the acidity of 
the proton provided can be controlled, the protonation face can be predicted. 
Protonation of enolates is thus a very important tool for the synthesis of 
polyketides.  
 
 In 2013, in an attempt to further the studies of the synthesis of reduced 
propionates and find faster transformation routes for the synthesis of the same, 
Hosokawa et al. realized that Birch reductions on α,β-unsaturated imides 
proceed in stereoselective manner via a chiral enolate.33 
 It was reported that after a vinylogous Mukaiyama aldol reaction (VMAR) 
of the vinylketene silyl N,O-acetal 26 and tiglic aldehyde 27, the adduct 
would then have the potential to be reduced sequentially and stereoselectively 
into a reduced propionate with desired stereochemistry (Scheme 1.7). This 
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versatile protocol and its application have found several usages in the 
synthesis of numerous natural products since then.34-39 
 
 While the unconjugated olefin in 28 was hydrogenated in the presence 
rhodium or platinum catalysts, the α,β-unsaturated imide was found to be 
reduced stereoselectively under the Birch reduction conditions where a metal 
such as sodium or lithium was dissolved in liquid ammonia (Scheme 1.8). If 
palladium was used to reduce the α,β-unsaturated imide, the stereochemistry 
obtained would be the reverse of the one achieved under the Birch conditions.  
 
 The change in the absolute stereochemistry of the newly generated C-2 
position going from the palladium reaction to the Birch reduction was 
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merited to the different intermediates in the two reactions. In the palladium 
reaction, due to the dipole-dipole interactions of the two carbonyl groups, the 
oxazolidinone ring flips in order to reduce the dipolar repulsion (Scheme 1.9). 
             
 
 The flipping of the oxazolidinone thus prohibits the hydrogenation of the 
substrate 29 from the bottom face, thereby leading to the formation of 
compound 31, with the newly formed asymmetric carbon bearing S-
configuration (Scheme 1.9). 
 The Birch reduction reaction, however, differs greatly from the Pd-catalyzed 
hydrogenation. The intermediate of the Birch reaction is chelated, such that 
free rotation of the oxazolidinone is restricted (Scheme 1.10). The 
protonation occurs only from the bottom face as the top face is hindered by 
the chiral auxiliary thereby providing 30 with the newly generated 
asymmetric carbon bearing R-configuration. 
 
 Thus, interestingly, the configuration of the C-2 position could be altered by 
either using the Pd catalyzed hydrogenation or the Birch reaction. 
 This methodology soon found an application in the total synthesis of (+)-
methynolide (34), an aglycon of the 12-membered antibiotic methymycin by 
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Kobayashi et al. (Scheme 1.11). In their synthesis of the macrocycle, one of 
the key approaches used was the Birch reduction of aldol adduct 32 to furnish 
the lactone 33 as a single isomer.40 The lactone was then further transformed 
to the macrocyclic methynolide in 10 steps. 
 
 Thus reduction of α,β-unsaturated imides under hydrogen atmosphere with 
Pd-catalyst or under the Birch reduction provided efficient and versatile 
methods for the synthesis of polyketides and deoxypropionates. 
1.5 Proton source methodology to quench enolates 
 The choice of proton source used to quench enolates also plays an important 
role in the stereochemistry of the asymmetric carbon that is generated.  
 In 2001, during the synthesis of methyl jasmonite 37, a conjugate addition 
and protonation sequence was attempted (Scheme 1.12). It was observed that 
when enone 35 was subjected to a 1,4-addition reaction with lithium 
diallylcuprate, followed by protonation of the enolate with 2-
(methyliminomethyl)phenol, a cis:trans ratio of 85:15 was realized.41 
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 Conversely, in the synthesis of methyl dihydrojasmonite (40) diastereomeric 
ratios were surprisingly better (Scheme 1.13). When the enone 38 was 
subjected to a 1,4-addition reaction with lithium diallylcuprate and the 
enolate quenched by 2-(methyliminomethyl)phenol, the diastereomeric ratio 
observed was 94:6 of 39. However, other proton sources such as ethyl 
salicylate or tert-butyl salicylate provided only 83:17 and 55:45 ratio of 
cis:trans isomers respectively. 
 
 The protonation mechanism is quite simple for the two cases of jasmonites 
(Scheme 1.14). After addition of the cuprate to the enone, the intermediate is 
somewhat planar. The allyl group blocks off the top face for protonation 
thereby allowing only the bottom face for the proton source.  
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 Hence, specific proton sources can stereoselectively quench enolates and can 
influence the stereochemistry of the newly generated chiral center.  
1.6 Motivation behind this dissertation 
 As mentioned earlier, protonation of enolates is an important methodology 
for the synthesis of reduced propionates and polyketides. It is interesting to 
study the change in the ratio of isomers formed from the protonation of 
enolates and correlate it to the increase in size of the proton source. There is 
no prior literature studying the effects of bulky proton sources to quench 
chiral enolates.  
 It is of primary importance to first screen myriad proton sources that can be 
used to quench enolates (Scheme 1.15). Chiral enolates that are generated in 
Birch reduction conditions can be used as intermediates for protonation with 
a variety of proton sources of different sizes and the ratio of epimers can be 
studied which will then provide evidence for the “size to ratio” correlation. 
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 With the protonation of enolates in mind, an isomerization reaction of an 
α,β-unsaturated imide to the β,γ-unsaturated imide could be accomplished. 
The β,γ-unsaturated imide can be used as an important intermediate for the 
synthesis of γ-lactones, a common structural backbone of several important 
depsipeptides.  
 Overall, this dissertation presents studies on the protonation of chiral 
enolates with bulky proton sources. This thesis aims to provide a newer and 
easier approach to the synthesis of reduced propionates and deoxypropionates. 
It is able to find important correlation between the size of the proton source 
that are used and the ratio of isomers obtained. The methodology is then 
applied in the synthesis of different natural products. 
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Chapter 2: Birch reduction and the synthesis of sex 
pheromone of Macrocentrus grandii 
2.1 Introduction 
 In 2016, during the synthesis of mycocerosic acid, 36 a component of virulent 
factor of Mycobacterium tuberculosis3, Hosokawa et al. found that when 
hindered substrate 43 was subjected to Birch conditions, 44 and epi-44 were 
formed (Scheme 2.1). The ratio of 44 and epi-44 changed with the change in 
proton source (Table 1). The best proton source was found to be 2-
methylbenzimidazole. 
 
Entry Proton source Diastereomeric ratioa Yield (%) 
1 ammonium chloride 2:1 72 
2 2,6-di-tert-butylphenol 2:1 86 
3 2-pyridone 4:1 61 
4 benzimidazole 12:1 86 
5 2-methylbenzimiadzole >20:1 81 
 a Determined by 400 MHz NMR 
       Table 1. Protonating agents in the total synthesis of mycocerosic acid 
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2.2 Optimization of reaction conditions 
 However, for less hindered substrates such as 45, 2-methylbenzimidazole 
only showed moderate selectivity. Therefore, screening for a proton source 
for the Birch reduction (Scheme 2.2, Table 2), it was found that when 
ammonium chloride (entry 1, Table 2), a very commonly used proton source 
for Birch reductions, was used to protonate the intermediate, the reaction 
proceeded with very low stereoselectivity. 
  
Entry Proton source 46: epi-46a Yield (%) 
1. ammonium chloride    1.9:1 59 
2. 2,6-di-tert-butyl phenol    1.5:1 60 
3 2-pyridone    1.5:1 54 
4 pthalimide    2.4:1 37 
5 benzimidazole    2.6:1 61 
6 2-methylbenzimidazole    3.8:1 64 
7 2-nonanoylbenzimidazole    4.0:1 44 
8 2-cyclohexylbenzimidazole    3.6:1 64 
9 2-isobutylbenzimidazole    3.1:1 68 
10 2-isopropylbenzimidazole    5.2:1 69 
11 2-tert-butylbenzimidazole    1.9:1 50 
12 2-n-butylbenzimidazole    3.4:1 60 
13 2-adamantylbenzimidazole    1.5:1 51 
14 N-(2,6-dimethylphenyl)pivalamide    1.4:1 54 
15 N-(2,6-diethylphenyl)pivalamide    1.3:1 60 
a Determined by 400 MHz NMR 
         Table 2. Protonation for less hindered α,β-unsaturated imide 45 
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 2,6-Di-tert-butylphenol (entry 2, Table 2), which is much bulkier in size, 
afforded slightly better results. 2-Pyridone (entry 3, Table 2), reported by 
Davies et al. as an excellent proton source42 for isopropyloxazolidinone based 
chiral auxiliaries, could not change the stereoselectivity.  
 As a bulky benzimidazole, 2-methylbenzimidazole (entry 6, Table 2) was 
tried, and 46 and epi-46 in the ratio of 3.8:1 were obtained. Even bulkier 2-
isopropylbenzimidazole (entry 10, Table 2) gave good stereoselectivity 
(5.2:1) with good yield (69%). It was also interesting that 2-
nonanoylbenzimidazole (entry 7, Table 2) gave a moderate ratio of the 
epimers but in poor yield. 
 On increasing the size of the substituent on the benzimidazole beyond 
isopropyl to tert-butyl (entry 11, Table 2) or adamantyl (entry 13, Table 2) 
proved detrimental to the reaction. Phenylpivalamides possessing alkyl 
substituents on the phenyl ring consist of a rather acidic proton (entries 14 
and 15, Table 2). However, it would seem as if acidity has less influence than 
bulkiness.  
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 The chelated intermediate33 (Fig. 3) of the Birch reduction is expected to be 
of planar nature where the proton source approaches the enolate from the 
bottom face due to the presence of the isopropyl group on the top face. Thus, 
the ensuing major isomer 46 has a methyl group on the β-face. 
 On realizing that there is perhaps still scope for improvement, the chiral 
auxiliaries were changed around in the hope that perhaps other auxiliaries 
such as 4-cyclohexyl or 5,5-dimethyl derivative of isopropyloxazolidinone 
may have better effect on the stereoselectivity (Scheme 2.3, Table 3). Using 
the Birch reduction somewhat restricted the choice of chiral auxiliaries that 
could be used as 4-benzyloxazolidinone or 5,5-diphenyl derivative of 
oxazolidinone could not be tried. 
           
Entry R1 R2 Diastereomeric ratio
a Yield (%) 
1 isopropyl H 3.8:1 64 
2 cyclohexyl H 3.5:1 48 
3 isopropyl Me 2.1:1 50 
                     a Determined by 400 MHz NMR 
 Table 3. Effects of the Birch reduction on changing chiral auxiliary 
 As evident from the above table, using 4-cyclohexyloxazolidinone (entry 2, 
Table 3) leads to a decrease in diastereomeric ratio and yield. The 5,5-
dimethyl derivative of oxazolidinone (entry 3, Table 3) exhibited an 
interesting case. It has been reported that the dimethyl groups have the ability 
to push the isopropyl moiety over the alkyl chain.43 However in this study, it 
seemed not to be the case. The reaction with 5,5-dimethyl derivative of 
isopropyloxazolidinone yielded lesser diastereomeric ratio and yield than 
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entry 1 itself. The reason for using 2-methylbenzimidazole as the proton 
source is its commercial availability. 
 It is to be noticed here, that while 44 was formed in excellent 
stereoselectivity, it was not so the case with 46. This is perhaps due to the 
lack of an extra stereo-controlling γ-methyl group to the enolate that is 
generated which is present in 43, but absent in 45.  
Further improvements on the afore-mentioned Birch conditions were tried. 
The metal atom was at first thought to have some effect on the 
stereoselectivity, but it was realized that the size and the nature of the metal 
had no bearing on the ratio of diastereomers as on changing from lithium to 
sodium, the reaction remained unperturbed.  
2.3 Birch reduction on R-carvone 
 Next the Birch reduction followed by the stereoselective protonation on 
other substrates such as R-carvone 49 (Scheme 2.4, Table 4) was tried. On 
protonation, a peculiar trend in the diastereomeric ratio was observed. 
                              
Entry Proton source Diastereomeric ratioa Yield (%) 
1 ammonium chloride44) 6:1 62 
2 2-methylbenzimidazole 6:1 68 
3 2-isopropylbenzimidazole 6:1 68 
4 2-tert-butylbenzimidazole 6:1 50 
         a Determined by 400 MHz NMR 
Table 4. Protonation of R-carvone 
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 The diastereomeric ratio remains the same despite the change in proton 
source. This result is expected and the reason behind this is two-fold. Firstly, 
the isopropene group is too far away from the enolate to induce a good 
stereoselectivity. Secondly, the isopropene moiety assumes an equatorial 
position. It is therefore understandable that increasing the bulkiness of the 
proton source has no effect on the ratio of diastereomers. 
2.4 Synthesis of pheromone of Macrocentrus grandii 
 With a clear understanding of Birch reductions with the newly introduced 
proton source and understanding its limitations, the synthesis of (3S, 5R, 6S)-
6-isopropyl-3,5-dimethyltetrahydro-2H-pyran-2-one 51, the sex pheromone 
of Macrocentrus grandii was attempted. The compound is a δ-lactone45 and 
controls the population Ostinia nubilalis, and hence is able to help in 
agriculture in an environmentally friendly manner.46 
                                                 
 
2.4.1 Previous syntheses of pheromone of Macrocentrus grandii 
 Since its isolation in 1993,45 the pheromone 51 has been synthesized by a 
few groups. One of the first ever synthesis of 51 was performed via an 
enzymatic reaction on the meso diol 52 to provide 54 which on oxidation 
furnished the terminal aldehyde 55 (Scheme 2.5).47 
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 The nucleophilic reaction with (E)-crotyl-(S,S)-boronate (56) gave the alkene 
57. After ozonolysis of the TBS protected 58, borohydride reduction and 
tosylation provided the tosylate 59 which was reduced with LAH to furnish 
60. Oxidative lactonisation with ruthenium provided the target molecule 51. 
Thus 51 was synthesized in 9 steps from the diol 52.47 
 A more recent synthesis48 involves the use of Oppolzer’s chiral auxiliary and 
the target molecule was synthesized in 6 steps from the chiral synthon 61 
(Scheme 2.6). 
 
 
23 
 
 
 The chiral synthon 61 was subjected to an asymmetric aldol reaction with 
isobutyraldehyde to furnish 63 at a diastereomeric excess of 84%. Reductive 
cleavage with LAH followed by tosylation provided 65. Iodination and 
further propionylation with propionyl chloride gave the ester 68. Cyclisation 
of ester 68 provided the target lactone 51. 
2.4.2 Optimization of reaction conditions for the synthesis of pheromone of 
Macrocentrus grandii  
 The development of a shorter synthesis of 51 in just 3 steps was achieved 
(Scheme 2.7). The first step of the synthesis was a vinylogous Mukaiyama 
aldol reaction with isobutyraldehyde and ent-26 to furnish the aldol adduct 69 
in 82% yield in >20:1 diastereomeric ratio. The screening of the proton 
source for the Birch reaction was then carried out (Table 5). With NH4Cl 
(entry 1, Table 5), a 10:1 ratio of 51 and epi-51 was formed. 2-
Methylbenzimidazole (entry 3, Table 5) furnished 51 in 14:1 ratio of 
diastereomers but 2-isopropylbenzimidazole provided 51 as a single isomer 
in 70% yield (entry 4, Table 5).  
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Entry Proton source Diastereomeric ratio a 
(51:epi-51) 
Yield 
(%) 
1 ammonium chloride 10:1 72 
2 2,6-di-tert-butylphenol 11.4:1 52 
3 2-methylbenzimidazole 14:1 74 
4 2-isopropylbenzimidazole >20:1 70 
     a Determined by 400 MHz NMR 
   Table 5. Protonation of 69 to furnish lactone 51 
 Hence, the synthesis of (3S,5R,6S)-6-isopropyl-3,5-dimethyltetrahydro-2H-
pyran-2-one 51 was achieved in 3 steps by using a vinylogous Mukaiyama 
aldol reaction, a stereoselective protonation with 2-isopropylbenzimidazole 
and lactonization. The spectroscopic data of 51 are in accordance with those 
of the reported literature.48 
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Chapter 3. Isomerization reaction and the formal synthesis 
of seragamide A and its congeners 
 
3.1 Introduction 
 
 During the synthesis of madindoline A, Hosokawa et al. reported that when 
70 was treated with NaHMDS and then alkylated with chloroalkyl ethers, 
there was an alkylation reaction that proceeded smoothly to furnish a 
quaternary carbon in a good stereoselectivity (Scheme 3.1).49 The reaction 
was believed to proceed via the enolate TS-70 and the isopropyl auxiliary, 
would cover the top face to achieve a stereoselective alkylation. The enolate 
is chelated and hence rotation around the C-N bond is restricted.  
 
 
 
3.2 Optimization of reaction conditions 
 
 The isomerization reaction converting an α,β-unsaturated imide into a β,γ-
unsaturated imide required a protonation of the dienolate instead of an 
alkylation (Scheme 3.2). The product formed then, could be an important 
starting point for a variety of complex natural products. Therefore, the 
reaction conditions were optimized for the protonation reaction (Table 6). 
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 Acetic acid is the most commonly used source of proton for quenching the 
dienolate reactions. However, it provided 73 or epi-73 with 1.1:1 
diastereomeric ratio at 90% yield (entry 1, Table 6). 2-
Isopropylbenzimidazole, which worked the best under Birch conditions, gave 
a good ratio of 15:1 but moderate yield of 67% (entry 4, Table 6). 2,6-Di-tert-
butylphenol only provided the diastereomers in a 4.5:1 ratio (entry 2, Table 
6). 2-tert-Butylbenzimidazole furnished the epimers in a 8:1 ratio at only 
50% yield (entry 5, Table 6). The best proton source was found to be 2-
methylbenzimidazole which provided the β,γ-unsaturated imide in a 20:1 
ratio of diastereomers at 85% yield (entry 3, Table 6). 
                 
   
Entry Proton source Diastereomeric ratioa Yield 
(%) 
1 acetic acid 1.1:1 90 
2 2,6-di-tert-butylphenol 4.5:1 88 
3 2-methylbenzimidazole 20:1 85 
4 2-isopropylbenzimidazole 15:1 67 
5 2-tert-butylbenzimidazole 8:1 50 
  a Determined by 400 MHz NMR 
        Table 6. Optimization of isomerization reaction 
 
 
27 
 
 Upon changing the oxazolidinone moiety, interesting results were obtained 
(Scheme 3.4, Table 7). 4-Benzyloxazolidinone, 4-cyclohexyloxazolidinone 
and 5,5-dimethyl derivative of isopropyloxazolidinone were used for trials. 
 
Entry R1 R2 Diastereomeric ratio
a Yield (%) 
1 isopropyl H 20:1 85 
2 isopropyl Me 12:1 80 
3 cyclohexyl H 15:1 82 
4 Benzyl H 12:1 88 
       a Determined by 400 MHz NMR 
   Table 7. Effects of protonation reaction on changing chiral auxiliary 
 
 From the above table it is evident that using 4-isopropyloxazolidinone served 
the best results (entry 1, Table 7). 5,5-Dimethyl derivative of 
isopropyloxazolidinone (entry 2, Table 7) provided 75 at a 12:1 ratio of 
diastereomers. It would seem that the dimethyl derivative is detrimental both 
for the Birch and isomerization reactions.  
 4-Cyclohexyloxazolidinone (entry 3, Table 7) provided the β,γ-unsaturated 
imide with 15:1 ratio of isomers and 4-benzyloxazolidinone (entry 4, Table 
7) furnished 75 with 12:1 ratio at 88% yield. 
 
3.3 Proof of absolute stereochemistry 
 
 To prove the absolute stereochemistry of 73 or epi-73, the olefin was 
hydrogenated to give epi-46 (Scheme 3.3). However, surprisingly, from the 
1H NMR it was ascertained that the hydrogenation of 73 led to the formation 
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of 46 only (Scheme 3.5). It was then realized that the structure of 73 needed 
revision along with the intermediate.  
 
            
  
 
 The reaction perhaps goes through the intermediate 76 where the 
oxazolidinone ring is perpendicular to the dienolate (Scheme 3.6). Thus the 
protonation is allowed only on the bottom face allowing the newly formed 
methyl group to assume the β-face as depicted below. 
 
 
 Although this transition state is uncommon, there is some preceding 
literature50 for the formation of unchelated intermediate such as 76. 
 Further, compound ent-45 was isomerized to give ent-epi-73 which was 
hydrogenated and hydrolyzed to give the acid 77 in 90% yield (Scheme 3.7). 
The spectroscopic data of the acid 77 is in accordance with those of the 
literature51. 
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3.4: Some previous methods for the synthesis of β,γ-unsaturated imides 
 
 It is noteworthy that while Evans’ alkylation could be an alternate route for 
the stereoselective synthesis of epi-73, it has proven to be significantly 
difficult (Scheme 3.8). In 1998, in a study of alkylation of chiral dienolates, 
Nakai et al. exhibited that methylation of (S,E)-4-isopropyl-3-(pent-2-enoyl) 
oxazolidin-2-one provided 43% of 79 at 88% de. 52 
                  
 
 However, the isomerization method thus serves to provide the β,γ-
unsaturated imide in higher yields and better stereoselectivity. 
 In 2007, a study on the synthesis of γ-butyrolactones53 showed poor 
stereoselectivity (diastereomeric ratio = 60:40) when (S,E)-4-isopropyl-3-(4-
phenylpent-3-enoyl)oxazolidin-2-one was methylated (Scheme 3.9). 
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 Thus, an isomerization reaction converting an α,β-unsaturated imide into a 
β,γ-unsaturated imide was achieved with 2-methylbenzimidazole as the 
proton source. The reaction was then applied to the formal synthesis of 
seragamide A and its congeners. 
 
3.5 Formal synthesis of seragamide A and its congeners 
 
 With the isomerization reaction optimized, a formal synthesis of seragamide 
A and its congeners was attempted. Seragamide A (82), jasplakinolide (83), 
and geodiamolide A (84) are cyclodepsipeptides with potent cytotoxic 
activity.54,55 
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 On closer inspection of these molecules, there appeared a common structure 
85 (Scheme 3.10). Retrosynthesis of the common structure surfaced a key 
intermediate, the lactone 87. The lactone could be synthesized from 45. 
Synthesis of the common structure 85 from the lactone 87 has already been 
reported.56 
 
             
 The forward synthesis was then embarked upon (Scheme 3.11). An 
isomerization reaction was carried out to provide 85% of epi-73. Hydrolysis 
followed by iodolactonisation furnished the iodolactone 86 as a single isomer. 
To understand the stereochemistry of 86, an nOe experiment was carried out. 
The two methyl groups interacted identically to the proton on C-3. Also, the 
two protons on the bottom face interacted at 2.5%, thereby conclusively 
proving the structure to be as described in Scheme 3.11. Removal of the 
iodine group in the presence of n-Bu3SnH/AIBN and degassed benzene under 
reflux conditions furnished the crucial lactone 87 in 84% yield.53 
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 One of the disadvantages of the deiodination reaction seemed to be an 
unwanted E1cb reaction which often led to 88 (Scheme 3.12). The problem 
was avoided by degassing benzene before use.  
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 The iodolactonisation is also an important step which provided the 
iodolactone as a single isomer. The mechanism is perhaps the following. The 
iodine attaches itself to the bottom face of the olefin due to the steric 
hindrance of the methyl on the top face. The carboxylate then attacks from 
the β-face to provide the iodolactone as a single isomer 86 (Scheme 3.13). 
 
  
 
 Thus, the formal synthesis of seragamide A and its congeners was completed. 
The key transformations included an isomerization reaction of the α,β-
unsaturated imide to the β,γ-unsaturated imide and a stereoselective 
iodolactonisation and deiodination. 
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Chapter 4: Total Synthesis of PF1163B 
4.1 Introduction 
 PF1163A (90) and PF1163B (91) are cyclodepsipeptides that were isolated 
from the fermentation broth of Pencillium sp.57 The structure elucidation was 
done by Nose et al. and the first total synthesis was achieved by Tatsuta et al. 
in 14 steps by a contiguous Wittig reaction, hydrogenation and protection 
sequence.58 
                                                 
 PF1163B (91) is a potent inhibitor of ergosterol biosynthesis and shows an 
IC50 value of 34 ng/ml.
59 Because of its complex structure and potent 
bioactivity, PF1163B (91) has been an attractive target for total synthesis. 
4.2 Previous synthetic studies on PF1163B  
 As mentioned earlier, Tatsuta et al. achieved the first total synthesis of 
PF1163B. The amino acid fragment was obtained from N-Boc-L-tyrosine 93 
by alkylation, followed by methylation and finally hydrolysis (Scheme 4.1). 
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 The non-peptide segment 98 was made from (R)-citronellol 96 in 12 steps by 
an iterative Wittig olefination and hydrogenation methods (Scheme 4.2). 
 
 
 Coupling of the two fragments 98 and 92, by Yamaguchi esterification 
followed by removal of the Boc and COOtBu groups and then cyclisation 
afforded PF1163B (91) (Scheme 4.3). 
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 In 2003, during a study on conformational analysis of PF1163B, Bouzza et 
al. found that the previously reported synthesis of the amino acid fragment 92 
led to 60:40 ratio of epimers after the first alkylation reaction at 70 °C 
(Scheme 4.4). However, the same reaction at room temperature led to 
minimal racemization (97:3). Also, the methylation reaction seemed difficult 
to drive to completion as the silyl protecting group got removed. So, to avoid 
these difficulties, the authors designed an improved synthesis starting from 
N-Boc-L-tyrosine methyl ester 101 (Scheme 4.5).60 
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 The authors treated N-Boc-L-tyrosine methyl ester 101 with 2-bromo-O-
benzyl-ethanol in presence of Cs2CO3 to afford 102 (Scheme 4.5). 
Methylation followed by hydrolysis provided the amino acid fragment 104. 
 
              
 In the synthesis of the non-peptide moiety, epi-98 was made from (S)-
citronellene 105 in three steps (Scheme 4.6). The aldehyde 106 was 
synthesized by the cleavage of the epoxide with periodic acid. Further 
treatment of the aldehyde by the Kobayashi and Knochel method with 
dipentylzinc furnished the alcohol epi-98. 
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 The acid fragment 104 and the alcohol epi-98 were fused with DCC and 
DMAP (Scheme 4.7). The Boc group was removed and the resulting free 
amine was condensed with 4-pentenoyl chloride to give 109. A ring closing 
metathesis reaction in the presence of Grubbs II catalyst served the protected 
alkene 110 which was then hydrogenated to provide PF1163B (91). 
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 For the studies in this thesis, the total synthesis of PF1163B was achieved in 
10 steps. On the retrosynthesis of the target molecule, it was required to 
synthesize the amino acid fragment 92 without the reported epimerization. 
The best way to synthesize 92 without the epimerization was to bring about 
the TBS protection at a later stage in the presence of a weak base such as 
imidazole, at room temperature or lower (Scheme 4.8). 
              
 
4.3 Retrosynthesis of PF1163B 
 The non-peptide moiety 98 would be synthesized stereoselectively using a 
vinylogous Mukaiyama aldol reaction and a stereoselective protonation using 
2-isopropylbenzimidazole (Scheme 4.9). Fusion of alcohol 98 with the acid 
92 to give the ester 99 and consequent deprotection and cyclization should 
lead to the formation of PF1163B (91). 
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4.4 Optimization of syn-VMAR 
 The vinylogous Mukaiyama aldol reaction (VMAR) is a well-reported and 
widely used reaction to synthesize propionates and acetates and propionate-
acetate frameworks (Scheme 4.10). Anti-selective VMARs to give 
propionates and acetate-propionate structures61 are reported along with syn-
selective VMAR to provide propionates.62 However, the need to establish a 
protocol to obtain the syn-selective acetate-propionate fragment is imminent. 
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 To study this type of VMAR, vinylketene silyl N,O-acetal ent-114 was used 
along with n-hexanal and optimized with different Lewis acids to afford 117 
(Scheme 4.11). The results are tabulated below (Table 8). 
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a Determined by 400 MHz NMR 
Table 8. Optimisation of syn-VMAR reactions 
 As evidenced by the table, the reaction appears to work best with 4 
equivalents of TiCl4 without the use of any additive (entry 1, Table 8). The 
Entry Eq. 
of 
ent-
114 
Lewis acid 
(eq.) 
Eq. of n-
hexanal 
Additive Diastereomeric 
ratio a (117: epi-
117) 
Yield 
(%) 
1 1.0 TiCl4 (4.0) 2.0 - 4.1:1 54 
2 1.5 TiCl4 (4.0) 1.0 - 4:1 5 
3 1.0 TiCl4 (4.0) 3.0 - 4:1 25 
4 1.0 SnCl4 
(1.0) 
1.5 - 1:20 70 
5 1.0 SnCl4 
(4.0) 
1.5 - 2:1 40 
6 1.0 BF3·OEt2 
(4.0) 
1.5 - 1:2 32 
7 1.0 TiCl4 (4.0) 1.5 MS 4Å 1.2:1 61 
8 1.0 TiCl4 (4.0) 1.5 LiI 2:1 40 
9 1.0 SnCl4 
(4.0) 
1.5 Cu(OTf)2 1.5:1 44 
 
 
43 
 
reaction was also dependent on the equivalents of ent-114 and the aldehyde 
(entries 2 and 3). Best results were achieved on using solutions of freshly 
distilled aldehyde and the Lewis acid. SnCl4, so commonly used in VMARs 
for the synthesis of acetate type moieties, did not function well in this case 
(entries 4, 5 and 9). The use of any additives seemed to be detrimental to the 
reaction conditions (entries 7, 8 and 9). 
 The reaction mechanism of syn-selective VMAR is not well understood,66 
while the anti-selective VMAR appears to be easier to comprehend (Scheme 
4.12). In the anti-selective case, the reaction proceeds through a favored T.S. 
A, while the T.S. B is disfavored due to steric repulsion between the R group 
of the aldehyde and the inner methyl group of the diene as well as between 
TiCl4 and the terminal methyl group.
41 
 
 In the syn-selective VMAR, however, the blue colour of the solution is 
different from the anti-selective VMAR which is red, thereby suggesting that 
the transition states are different.66 One argument for the moderate 
diastereomeric ratio is that in the case of syn-selective acetate-propionate 
type VMARs on ent-114, which does not possess a terminal methyl group 
(present in 26 and T.S. B) the aldehyde is free to move around and can take 
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up different positions at the time of reaction, thereby providing a moderate 
mixture of diastereomers.  
 This, however, cannot be the entire reason as the anti-selective VMAR 
proceeds with ent-114 in high diastereomeric ratio and yields.  
 Having found the best conditions for the acetate-propionate type VMARs, 
the reaction was attempted on other aldehydes (Scheme 4.13). 
              
 Isobutyraldehyde underwent the syn-VMAR smoothly to provide 118 in 
3.4:1 ratio at 50% yield while isovaleraldehyde provided its corresponding 
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syn adduct 119 in a diastereomeric ratio of 4.1:1 at 56% yield (Scheme 4.13). 
Phenylpropanal also worked well to give the alcohol 120 at a ratio of 3:1 in 
55% yield. However, attempts to recreate the reaction with paraldehyde, the 
trimer of acetaldehyde, proved unsatisfactory as the ratio of isomers plunged 
to 1.6:1. The reaction with paraldehyde is too fast to control, evidenced by 
the much higher yields, and hence the diastereoselectivity is compromised. 
 As noted above, the syn-VMAR gives moderate yields using silyldienol 
ether ent-114. The major side reaction is the protonation of the silyl ether ent-
114 to give the α,β-unsaturated imide 70 in the presence of higher equivalents 
of TiCl4 (Scheme 4.14). Any attempt to minimize the formation of the by-
product by the use of MS 4Å was thwarted by the decrease in diastereomeric 
ratio (entry 7, Table 8). 
 
 When vinylketene silyl N,O-acetal ent-114 was treated with unsaturated 
aldehydes such as benzaldehyde, p-bromobenzaldehyde and crotonaldehyde, 
the rate of protonation of ent-114 to give 70 seemed faster than the rate of the 
VMAR. Thus, the reaction failed to give syn-adducts with unsaturated 
aldehydes. Instead, quantitative amount of 70 can be recovered from the 
reaction mixture. 
 Having optimized the syn-VMAR reaction conditions, the total synthesis of 
PF1163B was embarked upon (Scheme 4.15).  
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4.5 Synthesis of non-peptide fragment 98 
 
 The syn-VMAR on 114 gave the aldol adduct 113 at a 4:1 ratio of 
inseparable diastereomers which were protected with TBS and the isomers 
separated to isolate 123 (Scheme 4.15). The Birch reduction on 123 was 
standardized with the use of different proton sources (Table 9). Ammonium 
chloride failed to give any diastereoselectivity (entry 1, Table 9), while 2-
methylbenzimidazole gave only moderate selectivity (entry 2, Table 9). 2-
isopropylbenzimidazole furnished the epimers in a 6:1 ratio (entry 3, Table 9), 
but on increasing the size of the substituent on benzimidazole beyond 
isopropyl, to tert-butyl, provided only a 2:1 ratio of diastereomers with 
reduced yield (entry 4, Table 9).  
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Entry Proton source Diastereomeric ratioa Yield (%) 
1 ammonium chloride 1.1:1 41 
2 2-methylbenzimidazole 4.4:1 64 
3 2-isopropylbenzimidazole 6:1 65 
4 2-tert-butylbenzimidazole 2:1 57 
a Ratio of isolated products 
 Table 9. Protonation in the Birch reduction of 123 
 DIBAl-H reduction of 124 and concomitant Horner-Wadsworth-Emmons 
reaction on the resulting aldehyde yielded the α,β,γ,δ-unsaturated ester 112 in 
70% in 2 steps at 23:1 ratio of diastereomers (Scheme 4.15). The diene was 
hydrogenated, and the TBS group removed to furnish the alcohol 98. The 
spectroscopic data of the alcohol 98 is in accordance with those of reported 
literature.58 
 The phosphonate 125 was prepared easily from commercially available tert-
butyl crotonate 126 by allylic bromination with NBS and AIBN in CCl4 
followed by an Arbuzov reaction (Scheme 4.17). 
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 It is noteworthy that the Horner-Wadsworth-Emmons reaction often led to 
substantial epimerization of the α-carbon and would depend on the 
temperature. When the ylide was generated at 0 °C, and the aldehyde was 
added at the same temperature the ratio of the diastereomers was realized to 
be 4:1. Generation of the ylide and addition of the aldehyde at -78 °C, led to a 
20:1 ratio of diasteromers but low yield (25%). A balance seemed to be found 
when the ylide was generated at -78 °C, then allowed to stir at -25 °C. After 
returning the reaction to lower temperature (-78 °C), the aldehyde was 
introduced and the resulting mixture was again stirred at -25 °C. This led to 
the least amount of epimerization of the C-2 position (dr = 23:1) and the 
α,β,γ,δ-unsaturated ester 112 was obtained in 70% yield from imide 124. 
4.6 Synthesis of acid fragment 92  
 With the alcohol 98 in hand, the amino acid fragment 92 was synthesized 
(Scheme 4.18). As stated earlier, in order to circumvent the epimerization, 
alkylation of N-Boc-L-tyrosine methyl ester 101 with 2-bromo-O-benzyl-
ethanol was carried out to give 102 in 56% yield. N-Methylation under 
reported conditions seemed difficult to drive to completion and the best 
conditions were the use of dry DMF to furnish 103 in 91% yield.  
Hydrogenation to remove the benzyl group, followed by TBS protection in 
CH2Cl2 and hydrolysis provided the amino acid fragment 92 in 40% in 3 
steps.  
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4.7 Completion of total synthesis of PF1163B 
 The acid 92 and the alcohol 98 were coupled using Yamaguchi esterification 
to give 99 in 78% yield (Scheme 4.19). Removal of Boc and tert-butyl ester 
with TFA was followed by an intramolecular amidation with BOPCl and 
TEA in CH2Cl2 to provide PF1163B (91) in 50% yield over 2 steps. 
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 Thus, PF1163B was synthesized successfully in 10 steps from the dienolate 
114. The major transformations included a stereoselective vinylogous 
Mukaiyama aldol reaction and a stereoselective Birch reduction with 2-
isopropylbenzimidazole as the proton source. Synthesis of the amino acid 
fragment was also achieved with minimum racemization. Successful fusion 
of the non-peptide fragment 98 and the amino acid derivative 53 led to the 
formation of the ester 99. A BOPCl mediated lactamization afforded the 
target molecule PF1163B (91).    
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Chapter 5. Synthetic studies on Spongidepsin 
5.1 Introduction 
 Spongidepsin (127, Fig. 4) is a macrolide isolated from the Vanatu islands, 
Australia by Riccio et al.63 It shows cytotoxic and anti-proliferative activities 
against J774.A1, WEHI-164 and HEK-293 cancer cell lines.63 Spongidepsin 
is a 13-membered cyclodepsipeptide comprising 5 stereogenic carbons. 63 The 
absolute configuration of 4 chiral carbons was determined by spectroscopic 
analysis, while the N-methylphenylalanine moiety with L configuration was 
assigned by spectroscopic studies and degradation.63 The unique structure and 
bioactivity make spongidepsin an attractive target for total synthesis. 
                                                       
5.2 First total synthesis of spongidepsin by Cossy et al. 
 Spongidepsin was first isolated in 2001.63 Since then, several groups have 
synthesized the target molecule and many others have achieved formal 
syntheses.64-66 One of the first total synthesis of spongidepsin was reported in 
2006 by Cossy et al.67 They achieved the synthesis in 14 steps with an overall 
yield of 13%.  
 The retrosynthetic analysis applied by the Cossy group has been closely 
followed by several other groups since (Scheme 5.1). 
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 The C1-C5 fragment was synthesized using commercially available Roche 
ester (Scheme 5.2). 
 
 Silyl protection of Roche ester 128 followed by DIBAL reduction gave the 
aldehyde 129. Crotylation with but-2-enyl-(tri-n-butyl)stannane 130 produced 
the syn-syn adduct 131.68 Removal of the hydroxyl group by mesylation and 
hydride reduction followed by TBAF reaction provided the primary alcohol 
133. Oxidation of the primary alcohol to carboxylic acid 134 was done by 
Jones’ reagent in acetone. 
 The C6-C13 fragment involved the protection of 5-hexenol with a silyl group 
and the ozonolysis of the olefin to give the aldehyde 136 (Scheme 5.3). A 
crucial reaction then was the transformation of the aldehyde 136 to 138 using 
a stereoselective conjugate addition reaction of a ketyl radical to an optically 
active α,β-unsaturated ester 137 mediated by samarium diiodide which then 
underwent intramolecular cyclisation to give the lactone 138.69 Methylation 
of the lactone provided 139 in a diastereomeric ratio of 5.7:1. DIBAL 
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reduction of the lactone to give the lactol was followed by Wittig reaction to 
furnish the terminal alkene 140. 
 
 The synthesis was completed with the Mitsunobu reaction of alcohol 140 
with the carboxylic acid 141 to give 142 (Scheme 5.4). Removal of the Boc 
group and condensation with 134 in the presence of EDCI gave 143. Ring 
closing metathesis with Grubbs-II catalyst provided 144 which was 
subsequently transformed to spongidepsin (127) in 4 steps. 
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5.3 Retrosynthesis of spongidepsin 
 This dissertation focuses on the concise synthesis of segments 134 and 145 
(Scheme 5.5). 
 
5.4 Synthesis of acid fragment 134 
 It was realized that 134 could be synthesized from the imide 146 by a Birch 
reduction followed by a metal reduction and hydrolysis (Scheme 5.6). 
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 The alcohol 145 could be achieved from the lactone epi-139, which in turn 
might be derived from the imide 147 by an analogous method to that of 
formal synthesis of seragamide A (Scheme 5.7). 
                            
 Thus, the synthesis of the acid fragment 134 was embarked upon (Scheme 
5.8). Vinylketene silyl N,O-acetal 26 was treated with commercially available 
bromoacetaldehyde diethyl acetal in presence of BF3•OEt2.
70 The reaction 
was temperature sensitive and did not proceed at -78 °C. However, raising it 
to room temperature led to the formation of four diastereomers. The best 
condition was found to be the addition of the Lewis acid to the acetal at -
78 °C and then after the addition of the vinylketene silyl N,O-acetal 26, 
raising of the temperature to 0 °C. The reaction took 10 hours to complete to 
furnish 149 as a mixture of 2 diastereomers in 9:1 ratio at 68% yield. It was 
determined that the 2 diastereomers were brought about by the change in 
stereochemistry of the ether linkage at C-7 and not by isomerism at C-6 
position.  
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 The stereoselective protonation of 149 proved to be challenging. On addition 
of lithium to 149, a dark blue solution appeared which was then quenched 
with 2-isopropylbenzimidazole (Scheme 5.9). This led to a single spot on the 
TLC, which on purification and analysis remained undetermined. The 
reaction showed no improvement on using a high equivalent of sodium either. 
        
 While an sp3-sp3 coupling is difficult to perform, especially at such low 
temperatures, there is a possibility that it may be case in the Birch reduction. 
Removal of the bromine moiety and the ether linkage by a reductive 
elimination before the stereoselective Birch reduction would be better to 
synthesize 134. Thus, reductive eliminations were carried out under different 
conditions (Scheme 5.10, Table 10). 
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Entry Metal Solvent Additive Temperature Notes 
1 Mg dry Et2O 1,2-
dibromoethane 
50 °C No reaction, 
149 
unconsumed. 
2 Mg dry THF Iodine 50 °C No reaction, 
149 
unconsumed 
3 Zn 
powder 
EtOH - reflux No reaction, 
149 
unconsumed 
4 Zn dust EtOH  - reflux No reaction, 
149 
unconsumed 
5 Zn dust EtOH NH4Cl 78 °C Multiple spots 
on TLC 
6 Zn dust EtOH NH4Cl 50 °C 150 formed in  
88% 
   Table 10. Trials for reductive elimination 
 When compound 149 was treated with Mg in either diethyl ether or THF, the 
reaction failed to progress with additives such as 1,2-dibromoethane or iodine 
(entries 1 and 2, Table 10). The reductive cleavage of α-bromoethers is 
reported in cyclic systems such as carbohydrates in the presence of zinc and 
refluxing ethanol, but the trials using zinc powder failed to produce 150 
(entry 3, Table 10). It was then thought that using a smaller particle size of 
zinc may propel the reaction forward. Disappointingly however, the reaction 
did not seem to proceed in zinc dust either in refluxing ethanol (entry 4, 
Table 10). NH4Cl is sometimes used as an additive in the presence of Zn dust 
to cleave cyclic iodoethers.71 When NH4Cl (10 eq.) was used along with Zn 
dust (15 eq.) in EtOH at 78 °C, the starting material disappeared on the TLC 
(entry 5, Table 10). However, it was ensued by multiple spots and it was 
impossible to separate. Lowering the temperature to 50 °C resulted in the 
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complete consumption of 149 to furnish 150 in 88% yield (entry 6, Table 10). 
The plausible mechanism for the elimination is shown below (Scheme 5.11). 
 
 The zinc inserts itself between the carbon-bromine bond by donating two 
electrons. Subsequent protonation of the ether by NH4Cl, and elimination 
results in the formation of 150. 
 It was noteworthy that the reaction seemed to work very fast under Zn dust 
(15 equivalents) and NH4Cl (10 equivalents), finishing in 40 minutes. Despite 
being a heterogeneous mixture in ethanol, the reaction was sensitive to the 
equivalents of zinc and ammonium chloride used. For example, when 5 
equivalents and 3 equivalents of zinc and ammonium chloride were used 
respectively, the reaction did not finish as some starting material remained 
even after 15 hours at 50 °C. 
 Stereoselective protonation of compound 150 under Birch conditions 
provided 151 in 64% yield at a diastereomeric ratio of >20:1 with 2-
isopropylbenzimidazole (Scheme 5.12). Removal of the oxazolidinone ring 
with LiOH•H2O and 30% H2O2 provided the required acid 134 in 70% yield.  
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 Thus, the acid fragment 134 was synthesized in 4 steps from 26. 
5.5 Synthetic studies on lactone epi-139 
 For the synthesis of the lactone epi-139, it was considered at first to 
synthesize the imide 147 via the phosphonate 155 by the condensation of 
oxazolidinone 152 with a phosphonic acid 153 (Scheme 5.13). However, 
efforts to synthesize the pivalate 154 were thwarted as it refused to react with 
the oxazolidinone 152 to furnish 155. 
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 The synthetic plan was then changed (Scheme 5.14). It was decided to 
first do the Horner-Wadsworth-Emmons reaction to give 161 followed by 
hydrolysis. The α,β-unsaturated acid could then be converted to the imide 
147. 
 
 The isomerization of the olefin proceeded smoothly to afford 70% of 162 
in a >20:1 ratio (Scheme 5.15). The β,γ-unsaturated imide 162 would be 
converted to the known lactone epi-139. 
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Chapter 6: Conclusion 
In conclusion, this thesis describes the synthesis of reduced propionates using 
2-isopropyl and 2-methylbenzimidazoles as bulky proton sources. 
In Chapter 1, a general introduction on the syntheses of reduced propionates 
and deoxypropionates has been provided.  
In Chapter 2, synthesis of deoxypropionates using the Birch reduction with 2-
isopropylbenzimidazole as the proton source has been disclosed. The reaction 
was then used for a facile synthesis of the sex pheromone of Macrocentrus 
grandii which is a natural enemy of the European corn borer Ostrinia 
nubilialis.  
In Chapter 3, an isomerization reaction has been developed where an α,β-
unsaturated imide was isomerized to the β,γ-unsaturated imide 
stereoselectively using 2-methylbenzimidazole. The isomerization reaction 
was then used to develop a formal synthesis of seragamide A and its 
congeners.  
In Chapter 4, a total synthesis of PF1163B has been achieved. PF1163B 
inhibits ergosterol biosynthesis and has an IC50 value of 34 ng/mL. For the 
purpose of the total synthesis, a syn-selective VMAR reaction was developed. 
The reaction, along with the stereoselective protonation with 2-
isopropylbenzimidazole under Birch conditions provided the total synthesis 
of PF1163B in 10 steps.   
In Chapter 5, a synthetic study on spongidepsin has been discussed. 
Spongidepsin has shown IC50 values for various cancer cell lines such as 
J774.A1, WEHI-164, HEK-293. Synthesis of C1-C6 segment has been 
achieved in four steps. The stereogenic center at the C4 position and the 
terminal olefin were synthesized by a vinylogous Mukaiyama aldol reaction 
followed by Zn-mediated reductive elimination of the bromo and ether 
groups. The Birch reduction with 2-isopropylbenzimidazole provided the 
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stereogenic center at C2 position. These procedures gave a concise synthesis 
of chiral 2,4- dimethyl-5-hexenoic acid.   
The reactions and the synthetic routes developed in this thesis may find usage 
elsewhere for the development of variety of synthetically challenging natural 
products and for the synthesis of polyketides and polypropionates. 
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Chapter 7: Experimental Procedures 
General methods: 
1H NMR spectra were recorded at 400 MHz using JEOL ECS 400 instrument. 
Coupling constants (J) have been reported in Hz. 13C NMR spectra were 
recorded at 100 MHz JEOL ECS instrument. Chemical shifts (δ) are 
mentioned in parts per million (ppm) and referenced to the residual solvent 
peak. Melting points (mp) have been determined by using Yanako MP-S3 
instrument. FT-IR spectra were collected using JEOL JIR-WINSPEC 50. 
HRMS and MS were measured using JEOL JMS-SX102A and JEOL JMS-
GCMateII. Optical rotations were obtained with JASCO P-2200. All 
reactions were monitored by analytical thin layer chromatography which was 
performed on 0.25 mm E. Merck silica gel plates (60F254) using UV light as 
the visualizing agent, an ethanol solution of p-anisaldehyde and an aqueous 
solution of potassium permanganate and heat as the developing agent. Flash 
and column chromatography were performed using Kanto Kagaku Ltd. Silica 
gel (60N neutral, particle size 0.040-0.063 mm) and Fuji Silysia Chemical 
Ltd. Silica gel (BW-820MH, particle size 6nm) respectively. 
 
Materials: 
Unless otherwise noted, all reactions were carried out under argon 
atmosphere with freshly distilled dry solvents. Dichloromethane was distilled 
from phosphorous pentoxide. DMF was distilled under reduced pressure with 
molecular sieves.  THF was distilled from lithium aluminium hydride. 
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(i) Synthesis of SexPheromone of Macrocentrus Grandii 
 
                    
Compound 69 
To a solution of i-PrCHO (0.27 mL, 2.95 mmol) in dichloromethane (3.7 mL) 
was added TiCl4 (0.16 mL, 1.47 mmoles) and ent-26 (500 mg, 1.47 mmol) as 
a solution in dichloromethane (15 mL) at -78 °C. After stirring for 28 hours, 
the reaction was quenched with pyridine (0.5 mL, 5.88 mmol). Then, a 
saturated aq. Rochelle salt (10 mL) and NaHCO3 (10 mL) were added. The 
reaction was then allowed to attain room temperature and stirred vigorously 
until the white slurry was completely dissolved. The resulting solution was 
then extracted with ethyl acetate (5 ml × 3). The combined organic layer was 
concentrated and purified by silica gel chromatography (n- hexane: EtOAc = 
3:1) to yield 69 (360 mg, 1.21 mmoles, 82%) as a light yellow oil. 
Rf value: 0.36 (n-hexane: EtOAc = 3:1) 
1H NMR (400 MHz, CDCl3) δ = 5.82 (dq, J = 10.5, 1.5 Hz, 1H), 4.56 (ddd, J 
= 9.0, 5.5, 4.0 Hz, 1H), 4.34 (dd, J = 9.0, 9.0 Hz, 1H), 4.18 (dd, J = 9.0, 5.5, 
1H), 3.18 (ddd, J = 8.0, 3.5, 3.0, 1H), 2.95 (OH, d, J = 3.0 Hz), 2.71 (ddq, J = 
10.5, 8.0, 7.0 Hz, 1H), 2.35 (qqd, J = 7.0, 7.0, 4.0 Hz, 1H), 1.95 (d, J = 1.5, 
3H), 1.86 (qqd, J = 7.0, 7.0, 3.5 Hz, 1H), 1.03 (d, J = 7.0 Hz, 3H), 0.96 (d, J 
= 7.0, 3H), 0.94 (d, J = 7.0, 3H), 0.93 (d, J = 7.0 Hz, 3 H), 0.92 (d, J = 7.0 Hz, 
3H). 
13C NMR (100 MHz, CDCl3) δ = 171.7, 154.5, 142.4, 131.0, 79.1, 63.4, 58.1, 
37.4, 29.1, 28.4, 20.6, 17.9, 15.8, 15.2, 14.7, 13.9 
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[α]D
25 = - 15.9 (c 1.02, CHCl3)  
IR (KBr): 3532, 2963, 2932, 2876, 1765, 1691, 1390, 1366, 1301, 1208, 997, 
776 cm-1 
HRMS (ESI): m/z [M+Na]+calcd for C16H27O4NNa: 320.1830; found: 
320.1832 
 
                     
 
Compound 51 
To a solution of the alcohol 69 (40 mg, 0.134 mmoles) in dry THF (1.6 mL) 
at -78 °C was added liq. NH3 and lithium (2.80 mg, 0.402 mmoles). The 
resulting dark blue solution was allowed to stir for 6 minutes at that 
temperature and a solution of 2-isopropylbenzimidazole (107.3 mg, 0.67 
mmoles) in dry THF (3.0 mL) was cannulated to the above mixture followed 
by the addition of NH4Cl (50.2 mg, 0.938 mmoles). The mixture was then 
allowed to warm to room temperature to remove NH3, concentrated and 
extracted with EtOAc three times (2.0 mL × 3). The combined organic layer 
was then concentrated and used in the next reaction without further 
purification. 
The crude mixture was dissolved in PhMe (1.6 mL) and TsOH• H2O was 
added. The resulting mixture was stirred at room temperature for 6 hours and 
quenched with aq. NaHCO3 (1.0 mL). The organic layer was extracted three 
times with EtOAc (1.5 mL × 3), dried over Na2SO4, concentrated and 
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purified by silica gel chromatography (n-hexane: EtOAc = 7:1) to furnish the 
lactone 51 (17.2 mg, 0.101 mmoles) as a colourless liquid in 70% yield in 2 
steps.  
Rf value: 0.67 (n-hexane: EtOAc = 3:1) 
1H NMR (400 MHz, CDCl3): δ = 3.84 (dd, J = 10.0, 2.0 Hz, 1H), 2.48 (dqd, J 
= 13.0, 7.0, 6.0 Hz, 1H), 1.99-1.81 (m, 3H), 1.40-1.29 (m, 1H), 1.28 (d, J = 
7.0 Hz, 3H), 1.08 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.0 Hz, 3H), 0.90 (d, J = 
7.0 Hz, 3H)  
13C NMR (100 MHz, CDCl3): δ = 174.9, 90.9, 37.7, 36.3, 31.2, 29.4, 19.9, 
17.3, 14.2 
[α]D
25 = - 32.1 (c 1.08, CHCl3) 
IR (KBr): 2966, 2935, 2877, 1727, 1462, 1380, 1261, 1216, 1192, 1121, 996, 
795 cm-1 
HRMS (ESI): m/z [M+Na]+ calcd for C10H18O2Na: 193.1199; found 193.1201. 
 
 
 
 
 
. 
 
(ii) Formal Synthesis of seragamide A 
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Compound 46 
To a solution of compound 45 (30.0 mg, 0.133 mmoles) in dry THF (1.2 mL) 
and liq. NH3 at -78 °C, was added lithium (2.8 mg, 0.4 mmoles) in small 
pieces. The dark blue solution was stirred at the same temperature for 5 
minutes. Then, a colourless solution of 2-isopropylbenzimidazole (106.6 mg, 
0.67 mmoles) in dry THF (1.5 mL) was added followed by NH4Cl (42.7 mg, 
0.80 mmoles). The reaction was allowed to stir at room temperature 
thereafter to allow the complete evaporation of liq. NH3. The reaction was 
then concentrated, diluted with H2O (1.0 mL), and the aqueous layer 
extracted three times with EtOAc (1.5 mL x 3). The combined organic layer 
was then dried over Na2SO4, concentrated and purified by silica gel 
chromatography to give 46 (17.6 mg, 0.077 mmoles, 69%) as a colourless oil 
and epi-46 (3.4 mg, 0.014 mmoles, 13%) 
Rf value: 0.39 (n-hexane: EtOAc= 4:1) 
Compound 46: 
1H NMR (400 MHz, CDCl3) δ = 4.46 (ddd, J = 8.9, 3.9, 3.5 Hz), 4.26 (dd, J = 
8.9, 8.1 Hz), 4.19 (dd, J = 8.9, 3.0 Hz, 1H), 3.84-3.73 (m, 1H), 2.34 (dqd, J = 
7.0, 7.0, 4.0 Hz, 1H), 1.79-1.64 (m, 1H), 1.45-1.29 (m, 3H), 1.13 (d, J = 6.5 
Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 7.0 Hz, 
3H)  
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 13C NMR (100 MHz, CDCl3) δ = 177.3, 153.7, 63.0, 58.4, 37.2, 36.2, 28.4, 
20.2, 17.9, 16.4, 14.6, 14.0. 
[α]D
29 = + 64.0 (c 1.70, CHCl3) 
HRMS-ESI: m/z [M+Na]+ calcd for C12H21O3NNa: 250.1414; found: 
250.1415  
IR (ATR): 2961, 1773, 1696, 1384, 1199, 990, 757 cm-1 
 
Compound epi-46 
1H NMR (CDCl3, 400 MHz) δ = 4.44 (ddd, J = 9.0, 3.9, 3.1 Hz, 1H), 4.25 (dd, 
J = 9.1, 8.1 Hz, 1H), 4.19 (dd, J = 9.0, 3.0 Hz, 1H), 3.79-3.69 (m, 1H), 2.34 
(qdd, J = 7.0, 7.0, 4.0 Hz, 1H), 1.74-1.64 (m, 1H), 1.40-1.25 (m, 3H), 1.19 (d, 
J = 7.0 Hz, 3H), 0.90 (d, J = 7.1 Hz, 3H), 0.89 (t, J = 7.1 Hz, 3H), 0.87 (d, J 
= 7.0 Hz, 3H) 
13C NMR (100 MHz, CDCl3) δ = 177.3, 153.7, 63.1, 58.4, 37.4, 35.2, 28.4, 
20.4, 17.9, 17.8, 14.6, 14.1 
[α]D
28 = + 93.3 (c 1.85, CHCl3) 
IR (ATR): 2961, 1773, 1696, 1384, 1198, 990, 774 cm-1 
HRMS-ESI: m/z [M+Na]+ calcd for C12H21O3NNa: 250.1414; found: 
250.1411. 
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Compound epi-73 
To a solution of compound 45 (20 mg, 0.088 mmoles) in dry THF (0.80 ml) 
at -78 °C, was added a freshly prepared solution of NaHMDS 1.0 M in THF 
(97.6 µL, 0.098 mmoles) and stirred at the same temperature for 2 hours. A 
solution of 2-methylbenzimidazole (34.9 mg, 0.264 mmoles) in dry THF 
(0.50 mL) was then added. The reaction mixture was allowed to warm to 
room temperature and aq. NH4Cl (1.0 mL) was added and the mixture 
extracted three times with EtOAc (2.0 mL × 3). The combined organic layer 
was dried over Na2SO4, concentrated, and purified by silica gel 
chromatography several times (Toluene: EtOAc = 98:2) to give compound 
epi-73 (16.9 mg, 0.075 mmoles, 85%) as a colourless oil. 
Rf value: 0.30 (n-hexane: EtOAc= 4:1) 
1H NMR (400 MHz, CDCl3) δ = 5.69 (dq, J = 15.1, 6.5 Hz, 1H), 5.56 (ddq, J 
= 15.1, 7.0, 1.5 Hz, 1H), 4.51-4.42 (m, 2H), 4.26 (dd, J = 9.0, 8.5 Hz, 1H), 
4.18 (dd, J = 9.0, 3.0 Hz, 1H), 2.32 (qqd, J = 7.0, 7.0, 4.0 Hz), 1.67 (dd, J = 
6.5, 1.5 Hz, 3H), 1.23 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 7.0 Hz), 0.84 (d, J = 
7.0 Hz, 3H)  
13C NMR (100 MHz, CDCl3): δ = 175.2, 153.6, 129.9, 127.8, 63.0, 58.2, 40.4, 
28.2, 17.9, 17.9, 16.8, 14.5 
[α]D
28 = + 30.7 (c 1.41, CHCl3) 
IR (ATR): 2966, 1772, 1697, 1365, 1299, 1199, 968, 772 cm-1 
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HRMS (ESI): m/z [M+Na]+ calcd for C12H19O3NNa: 248.1257; found: 
248.1256. 
 
                       
Compound ent-epi-73 
To a solution of compound ent-45 (25 mg, 0.111 mmoles) in dry THF 
(1.0ml) at -78 °C, was added a freshly prepared solution of NaHMDS 1.0 M 
in THF (122.0 µL, 0.122 mmoles) and stirred at the same temperature for 2 
hours. A solution of 2-methylbenzimidazole (44.0 mg, 0.333 mmoles) in dry 
THF (0.80 mL) was then added. The reaction mixture was allowed to warm 
to room temperature and an aq. NH4Cl (1.5 mL) was added and the mixture 
extracted three times with EtOAc (2.0 mL × 3). The combined organic layer 
was dried over Na2SO4, concentrated, and purified by silica gel 
chromatography several times (Toluene: EtOAc = 98:2) to give compound 
ent-epi-73 (21.2 mg, 0.094 mmoles, 86%) as a colourless oil. 
Rf value: 0.30 (n-hexane: EtOAc= 4:1) 
1H NMR (400 MHz, CDCl3) δ = 5.69 (dq, J = 15.1, 6.5 Hz, 1H), 5.56 (ddq, J 
= 15.1, 7.0, 1.5 Hz, 1H), 4.51-4.42 (m, 2H), 4.26 (dd, J = 9.0, 8.5 Hz, 1H), 
4.19 (dd, J = 9.0, 3.0 Hz, 1H), 2.32 (qqd, J = 7.0, 7.0, 4.0 Hz), 1.67 (dd, J = 
6.5, 1.5 Hz, 3H), 1.23 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 7.0 Hz), 0.84 (d, J = 
7.0 Hz, 3H)  
13C NMR (100 MHz, CDCl3): δ = 175.2, 153.6, 129.9, 127.8, 63.0, 58.2, 40.4, 
28.2, 17.9, 17.9, 16.8, 14.5 
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[α]D
28 = - 28.0 (c 1.30, CHCl3) 
IR (ATR): 2966, 1772, 1697, 1365, 1299, 1199, 968, 772 cm-1 
HRMS (ESI): m/z [M+Na]+ calcd for C12H19O3NNa: 248.1257; found: 
248.1257. 
                              
Compound 77 
To a solution of ent-epi-73 (50 mg, 0.220 mmoles) in EtOH (2 mL) was 
added 10% Pd/C (5 mg, 10 mol%) and stirred at room temperature for 3 
hours under hydrogen atmosphere. The reaction was then filtered through a 
cake of celite, and the filtrate was concentrated to give ent-46 as a colourless 
oil. Without further purification, crude ent-46 was dissolved in THF/H2O (2 
mL, 1:1 v/v) and LiOH•H2O (27.7 mg, 0.660 mmoles) and 30% H2O2 (0.15 
mL, 0.660 mmoles) were added and the reaction was stirred at room 
temperature for 4 hours. The reaction was then quenched with 2 M HCl till 
pH 3. The organic layer was extracted three times with EtOAc (3 × 2.0 mL), 
dried over Na2SO4, concentrated and purified by silica gel chromatography to 
yield 77 (23.0 mg, 0.198 mmoles, 90%) as a colourless oil. The spectroscopic 
data of 77 are in accordance with the literature value.1 
1H NMR (400 MHz, CDCl3): δ = 2.54-2.44 (m, 1H), 1.72-1.63 (m, 1H), 1.47-
1.31 (m, 3H), 1.18 (d, J = 6.8 Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H)  
13C NMR (100 MHz, CDCl3) δ = 183.4, 39.1, 35.6, 20.3, 16.8, 13.9 
[α]D
26 = + 17.4 (c 1.45, CHCl3) 
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 IR (ATR): 2961, 1702, 1244, 933 cm-1 
HRMS (ESI) : m/z [M-H]+ calcd for C10H18O2: 115.0765; found 115.0767 
 
                           
Compound 46 
To a solution of compound epi-73 (30.0 mg, 0.133 mmoles) in EtOH (1.2 
mL) was added Pd/C (2.8 mg, 10 mol%) and stirred at room temperature for 
3 hours. The reaction mixture was then filtered, concentrated and purified by 
silica gel chromatography to give 46 (30.1 mg, 0.077 mmoles, 99%) as a 
colourless oil. 
Rf value: 0.39 (n-hexane: EtOAc= 4:1) 
1H NMR (400 MHz, CDCl3) δ = 4.46 (ddd, J = 8.9, 3.9, 3.5 Hz), 4.26 (dd, J = 
8.9, 8.1 Hz), 4.19 (dd, J = 8.9, 3.0 Hz, 1H), 3.84-3.73 (m, 1H), 2.34 (dqd, J = 
7.0, 7.0, 4.0 Hz, 1H), 1.79-1.64 (m, 1H), 1.45-1.29 (m, 3H), 1.13 (d, J = 6.5 
Hz, 3H), 0.92 (t, J = 7.0 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H), 0.88 (d, J = 7.0 Hz, 
3H)  
 13C NMR (100 MHz, CDCl3) δ = 177.3, 153.7, 63.0, 58.4, 37.2, 36.2, 28.4, 
20.2, 17.9, 16.4, 14.6, 14.0. 
[α]D
29 = + 64.0 (c 1.70, CHCl3) 
HRMS-ESI: m/z [M+Na]+ calcd for C12H21O3NNa: 250.1414; found: 
250.1415  
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IR (ATR): 2961, 1773, 1696, 1384, 1199, 990, 757 cm-1 
 
                             
Compound 86 
To a solution of compound epi-73 (30 mg, 0.133 mmoles) in THF/H2O (1.2 
mL 1:1 v/v) was added LiOH•H2O (11.2 mg, 0.266 mmoles) and 30% H2O2 
(27.9 µL, 0.266 mmoles). The reaction was allowed to stir at room 
temperature for 2 hours. The reaction was then extracted twice with EtOAc 
(2.0 mL × 2) and the combined aqueous layer was treated with 1 M HCl until 
pH 3. The resulting solution was then again extracted with CHCl3 and the 
combined organic layer was dried over Na2SO4, and concentrated in vacuo. 
The resulting acid was used in the next reaction without further purification. 
To the crude acid in H2O (1.2 mL) was added Oxone™ (163.5 mg, 0.532 
mmoles) and KI (44.2 mg, 0.266 mmoles). The mixture was then stirred at 
room temperature for 2 hours. The reaction was quenched with aq. Na2S2O3 
(2.0 mL) and extracted with EtOAc twice (4.0 mL × 2). The combined 
organic layer was then dried over Na2SO4, concentrated in vacuo and purified 
by silica gel chromatography (n-hexane: EtOAc = 10:1) to give the 
iodolactone 86 (16.0 mg, 0.066 mmoles, 50% in 2 steps) as a colourless 
liquid. 
Rf value: 0.67 (n-hexane: EtOAc = 4:1) 
1H NMR (400 MHz, CDCl3): δ = 4.63 (dq, J = 10.0, 6.5 Hz, 1H), 3.56 (dd, J 
= 12.0, 10.0 Hz, 1H), 2.81 (dq, J = 12.0, 7.0 Hz, 1H), 1.50 (d, J = 6.5 Hz, 3H), 
1.33 (d, J = 7.0 Hz, 3H)     
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13C NMR (100 MHz, CDCl3): δ = 175.2, 82.2, 47.0, 26.7, 17.4, 12.4 
[α]D
29 = - 23.6 (c 1.32, CHCl3) 
IR (ATR): 2973, 1762, 1382, 1338, 1170, 1036, 950, 896, 746 cm-1 
HRMS (ESI): m/z [M+Na]+ calcd for C6H9O2INa: 262.9539; found: 262.9540 
 
                                       
Compound 87 
To a solution of the iodolactone 86 (40 mg, 0.166 mmoles) in degassed 
benzene (1.60 mL) was added TBTH (49.2 µL, 0.183 mmoles) and AIBN 
(5.5 mg, 0.032 mmoles). The mixture was then heated at 80 °C for 12 hours. 
The solution was then cooled, concentrated and purified by silica gel 
chromatography (n-hexane: EtOAc = 5:1) to give the lactone 87 (15.4 mg, 
0.135 mmoles, 82%) as a colourless oil.  
Rf value: 0.36 (n-hexane: EtOAc = 4:1) 
1H NMR (400 MHz, CDCl3): δ = 4.47 (dqd, J = 10.5, 6.5, 5.9 Hz, 1H), 2.68 
(ddq, J = 12.0, 8.5, 7.0 Hz, 1H), 2.51 (ddd, J = 12.9, 8.5, 5.1 Hz, 1H), 1.54-
1.44 (m, 1H), 1.42 (d, J = 6.5 Hz, 3H), 1.27 (d, J = 7.0 Hz)   
13C NMR (100 MHz, CDCl3): δ = 179.6, 74.9, 39.1, 36.4, 20.9, 15.1 
[α]D
30 = - 4.2 (c 0.21, CHCl3) 
IR (KBr) : 2922, 2357, 2341, 1770, 1759, 1375, 1246, 1056 cm-1 
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HRMS (ESI): m/z [M + Na]+ calcd for C6H10O2Na : 137.0573; found 137.0573. 
 
(iii) Total Synthesis of PF1163B 
General Procedure for syn-VMAR 
             
To a solution of the appropriate aldehyde (0.614 mmoles) and ent-114 (0.307 
mmoles) in CH2Cl2 (2.0 mL) at -78 °C was added TiCl4 (1.228 mmoles) at 
one time. The resulting deep blue solution was stirred for 12 hours and 
quenched with pyridine (4.912 mmoles). An aq. solution of NaHCO3 (2.0 
mL) was then added and the resulting mixture was raised to room 
temperature. The mixture was filtered through celite and the filtrate was 
extracted three times with CHCl3 (3 × 2.0 mL). The combined organic layer 
was dried over Na2SO4, concentrated and purified by silica gel 
chromatography to provide syn-VMAR adduct as an inseparable mixture of 
diastereomers.   
 
Compound ent-113 
Yield: 50.7 mg, 0.163 mmoles, 53%, dr = 4.1:1. 
1H NMR (400 MHz, CDCl3): 6.06-5.97 (1H, m), 4.52 (1H, ddd, J = 9.1, 5.0, 
5.0 Hz), 4.33 (1H, dd,  J = 9.1, 8.9 Hz), 4.21 (1H, dd, J = 9.1, 5.0 Hz), 3.77-
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3.68 (1H, m), 2.45-2.23 (3H, m), 1.95 (3H, s), 1.87-1.23 (15H, m), 0.96-0.85 
(9H, m) 
13C NMR (100 MHz, CDCl3): 171.5, 154.3, 135.3, 133.0, 70.6, 63.4, 58.1, 
36.8, 36.7, 31.8, 28.3, 25.6, 22.6, 17.8, 15.1, 14.1, 13.7 
[α]D
27 = +` 43.7 (c 1.10, CHCl3) 
IR (ATR): 3369, 2958, 2930, 1770, 1686, 1298, 1204, 754 cm-1 
HRMS-ESI: m/z [M + Na]+calcd for C17H29O4NNa: 334.1989; found 
334.1988. 
 
Compound 118 
Yield: 43.6 mg, 0.152 mmoles, 50%, dr = 3.4:1. 
1H NMR (400 MHz, CDCl3): 6.07-5.99 (1H, m), 4.52 (1H, ddd, J = 9.0, 5.0, 
5.0 Hz), 4.32 (1H, dd, J = 9.0, 8.5 Hz), 4.20 (1H, dd,  J = 9.0, 5.0 Hz), 3.50-
3.41 (1H, m), 2.58 (1H, brd, J = 3.9 Hz), 2.44-2.25 (3H, m), 1.95 (3H, d, J = 
1.0 Hz), 1.79-1.67 (1H, m), 0.98 (3H, d, J = 7.0 Hz), 0.95 (3H, d, J = 7.0 Hz), 
0.93 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.0 Hz) 
13C NMR (100 MHz, CDCl3): 171.6, 154.0, 134.6, 133.4, 75.8, 63.5, 58.3, 
33.5, 33.1, 28.6, 18.7, 18.1, 17.8, 14.9, 13.9 
[α]D
26 = + 71.4 (c 1.22, CHCl3) 
IR (KBr): 3530, 2962, 2875, 1774, 1686, 1365, 1294, 1209, 1053, 774, 754 
cm-1 
 
 
77 
 
HRMS-ESI: m/z [M + Na]+calcd for C15H25O4NNa: 306.1676; found 
306.1671. 
 
Compound 119 
Yield: 51.2 mg, 0.172 mmoles, 56%, dr = 4.2:1. 
1H NMR (400 MHz, CDCl3): 6.07-5.98 (1H, m), 4.52 (1H, ddd, J = 9.1, 5.0, 
5.0 Hz), 4.32 (1H, dd, J = 9.1, 8.9 Hz), 4.21 (1H, dd, J = 9.1, 5.0 Hz), 3.86-
3.76 (1H, m), 2.61-2.58(0.8 H, m), 2.45-2.22 (3H, m), 1.96 (3H, d, J = 1.0 
Hz), 1.88-1.76 (1H, m), 1.54-1.46 (1H, m), 1.30-1.21 (1H, m), 0.95-0.89 
(12H, m) 
13C NMR (100 MHz, CDCl3): 171.6, 154.0, 133.6, 133.6, 69.1, 63.5, 58.3, 
46.1, 36.7, 28.3, 24.7, 23.3, 22.1, 17.9, 14.9, 14.0. 
[α]D
17 = + 7.2 (c 1.02, CHCl3)  
IR (KBr): 3507, 2955, 2870, 1789, 1689, 1367, 1298, 1217, 777, 753 cm-1 
HRMS-ESI: m/z [M + H]+calcd for C16H28O4N: 298.2013; found 298.2008. 
 
Compound 120 
Yield: 57.3 mg, 0.165 mmoles, 54%, dr = 3:1. 
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1HNMR (400 MHz, CDCl3): 7.31-7.17 (5H, m), 6.03-5.94 (1H, m), 4.52 (1H, 
ddd, J = 9.0, 4.9, 4.9 Hz), 4.33 (1H, dd, J = 9.1, 9.0 Hz), 4.21 (1H, dd, J = 9.0, 
4.9 Hz), 2.90-2.80 (1H, m), 2.79-2.65 (2H, m), 2.47-2.30 (3H, m), 1.95 (3H, 
d, J = 1.1 Hz), 1.94-1.76 (3H, m), 0.93 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 
7.0 Hz) 
13C NMR (100 MHz, CDCl3): 171.5, 154.1, 142.1, 134.8, 133.9, 133.1, 128.5, 
128.3, 125.7, 70.2, 63.5, 58.2, 38.6, 36.2, 32.1, 28.2, 17.8, 14.9, 14.0 
 [α]D
17 = + 8.7 (c 0.96, CHCl3) 
IR (ATR): 3522, 2964, 1771, 1681, 1296, 1204, 747, 699 cm-1 
HRMS-ESI: m/z [M + H]+calcd for C20H28O4N: 346.2013; found 346.2008 
 
Compound 121 
Yield: 50.2 mg, 0.197 mmoles, 64%, dr = 1.6:1. 
1H NMR (400 MHz, CDCl3): 6.06-5.98 (1H, m), 4.59-4.49 (1H, m), 4.34 (1H 
(minor isomer), dd, J = 9.5, 9.0 Hz), 4.33 (1H (major isomer), dd, J = 9.5, 9.0 
Hz), 4.23-4.16 (1H, m), 3.99-3.88 (1H, m), 2.81 (brs, 0.36H), 2.61 (0.57H, 
brs), 2.45-2.24 (3H, m), 1.97-1.93 (3H, m), 1.26 (3H (minor isomer), d, J = 
7.0 Hz), 1.26 (3H (major isomer), d, J = 6.5 Hz) 0.93 (3H, d, J = 7.0 Hz), 
0.92 (3H  (minor isomer), d, J = 7.0 Hz), 0.91 (3H (major isomer), d, J = 7.0 
Hz) 
13C NMR (100 MHz, CDCl3): 171.5, 154.2, 154.0, 134.9, 133.5, 133.4, 133.0, 
67.1, 66.7, 63.4, 63.4, 58.2, 58.1, 38.3, 37.8, 28.3, 28.2, 22.7, 22.6, 17.8, 15.0, 
14.9, 13.9, 13.7 
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[α]D
17 = + 5.8 (c 1.26, CHCl3)  
IR (ATR):  3516, 2966, 1771, 1678, 1294, 1202, 752, 729 cm-1 
HRMS-ESI: m/z [M + H]+calcd for C13H22O4N: 256.1543; found 256.1540. 
 
         
Compound 125 
To a solution of 126 (500.0 mg, 3.516 mmoles) in CCl4 (20.0 mL), NBS 
(688.4 mg, 3.868 mmoles) and AIBN (57.7, 0.352 mmoles) was added and 
the resulting mixture was refluxed for 8 hours. The solution was then filtered, 
concentrated and the residue taken up in PhMe (20.0 mL) and P(OEt)3 (0.63 
mL, 3.70 mmoles) was added. The resulting solution was then refluxed for 26 
hours and concentrated. The residue was purified by silica gel 
chromatography (n-hexane: EtOAc = 1/2) to afford 125 (685.0 mg, 2.461 
mmoles, 70% in 2 steps) as a colourless oil.  
Rf value: 0.76 (100% EtOAc) 
1H NMR (400 MHz, CDCl3) δ = 6.75 (1H, ddd, J = 15.5, 6.9, 6.9 Hz), 5.92-
5.83 (1H, m), 4.18-4.03 (4H, m), 2.70 (2H, ddd, J = 23.0, 8.0, 1.0 Hz), 1.47 
(9H, s), 1.33 (3H, t, J = 7.0 Hz) 
13C NMR (100 MHz, CDCl3) δ = 165.0, 164.9, 136.0, 135.9, 127.7, 127.6, 
80.6, 62.3, 62.2, 31.1, 29.7, 28.1, 16.4, 16.3  
HRMS-ESI: m/z [M + Na]+calcd for C12H23O5NaP: 301.1175; found 
301.1174 
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IR (ATR): 2980, 1710, 1652, 1250, 1162, 1019, 961, 843, 731 cm-1 
                          
 
 Compound 113 
To a solution of n-hexanal (75.3 µL, 0.614 mmoles) and 114 (100.0 mg, 
0.307 mmoles) in CH2Cl2 (2.0 mL) at -78 °C was added TiCl4 (134.6 µL, 
1.228 mmoles) at one time. The resulting deep blue solution was stirred for 
12 hours and quenched with pyridine (0.40 mL, 4.912 mmoles). An aq. 
solution of NaHCO3 (2.0 mL) was then added and the reaction was raised to 
room temperature. The mixture was filtered through celite and the filtrate 
extracted three times with CHCl3 (3 × 2.0 mL). The combined organic layer 
was dried over Na2SO4, concentrated and purified by silica gel 
chromatography to provide 113 (50.7 mg, 0.162 mmoles, 54%) as an 
inseparable mixture of diastereomers. 
 
 
Compound 123 and epi-123 
To a solution of the compound 113 (104.0 mg, 0.333 mmoles) in CH2Cl2 (4.0 
mL) at 0 °C, was added 2, 6-lutidine (77.1 µL, 0.666 mmoles) and TBSOTf 
(0.115 mL, 0.500 mmoles) and stirred at room temperature for 20 minutes. 
After the complete consumption of starting material, the reaction was 
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quenched with aq. NaHCO3 (3.0 mL). The aqueous layer was extracted twice 
with CH2Cl2 (4.0 mL × 2) and the combined organic layer was concentrated 
and purified by silica gel column chromatography several times (PhMe: Et2O 
= 99:1 to 96:4) to furnish compound 123 (113.0 mg, 0.265 mmoles) and epi-
123 (28.8 mg, 0.067 mmoles) in quantitative yield.   
Rf value = 0.38 (n-hexane: EtOAc = 4:1) 
Major isomer (compound 123): 
1H NMR (400 MHz, CDCl3): 6.17 (1H, ddq, J = 7.1, 7.1, 1.1 Hz), 4.52 (1H, 
ddd, J = 9.1, 6.0, 5.0 Hz), 4.31 (1H, dd, J = 9.1, 8.9 Hz), 4.16 (1H, dd, J = 9.1, 
5.0 Hz), 3.82-3.74 (1H, m), 2.41-2.29 (3H, m), 1.90 (3H, s), 1.48-1.19 (10H, 
m), 0.94- 0.85 (18H, m), 0.04 (6H, s)  
13C NMR (100 MHz, CDCl3) =.171.8, 153.6, 136.4, 131.7, 71.3, 63.3, 58.2, 
37.2, 36.3, 31.9, 28.2, 25.8, 25.0, 22.6, 17.9, 15.0, 14.0, 13.8, -4.5, -4.6 
[α]D
24 = - 31.9 (c 1.05, CHCl3) 
HRMS-ESI: m/z [M + Na]+calcd for C23H43O4NNaSi: 448.2854; found 
448.2856  
IR (ATR): 2928, 1785, 1682, 1295, 1202, 1055, 834, 773 cm-1 
Minor isomer (compound epi-123): 
1H NMR (400 MHz, CDCl3): δ = 6.16 (1H, ddq, J = 7.0, 7.0, 1.5 Hz), 4.51 
(1H, ddd, J = 9.5, 5.9, 4.5 Hz), 4.30 (1H, dd, J = 9.0, 8.9 Hz), 4.17 (1H, dd, J 
= 8.9, 5.1 Hz), 3.81-3.74 (1H, m), 2.40-2.31 (3H, m), 1.91 (3H, d, J = 1.5 Hz), 
1.50-1.20 (10H, m), 0.92 (3H, d, J = 7.0 Hz), 0.89 (3H, d, J = 6.9 Hz), 0.87 
(9H, s), 0.04 (3H, s), 0.04 (3H, s).     
13C NMR (100 MHz, CDCl3) δ = 171.8, 153.5, 136.1, 132.0, 71.3, 63.4, 58.3, 
36.3, 31.9, 28.2, 25.8, 25.7, 25.0, 22.6, 17.9, 15.0, 14.0, 13.9, -4.5, -4.6. 
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 [α]D
24 = - 39.7 (c 1.17, CHCl3) 
HRMS-ESI: m/z [M + Na]+calcd for C23H43O4NNaSi: 448.2854; found 
448.2854 
IR (ATR): 2928, 1785, 1682, 1295, 1202, 1055, 834, 773 cm-1 
         
 
Compound 124 and epi-124 
To a solution of compound 123 (40.0 mg, 0.093 mmoles) in dry THF (1.6 
mL) and liq NH3 at -78 °C, was added lithium (2.6 mg, 0.372 mmoles) in 
small portions. After stirring the resulting deep blue solution for about 10 
minutes, a solution of 2-isopropylbenzimidazole (74.5 mg, 0.465 mmoles) in 
dry THF (2.5 mL) was added which was followed by the addition of NH4Cl 
(34.8 mg, 0.651 mmoles). The reaction was allowed to warm to room 
temperature to remove NH3. The reaction mixture was then concentrated, and 
the aqueous layer was extracted three times with EtOAc (3.0 mL × 3). The 
combined organic layer was evaporated and the residue was purified by silica 
gel column chromatography (n-hexane: EtOAc: 100:0 to 94:6) to yield 
compound 124 (26.1 mg, 0.061 mmoles, 65%) and epi-124 (4.3 mg, 0.010 
mmoles, 10.3%) as colourless oils. 
Major isomer 124: 
Rf value = 0.23 (n-hexane: EtOAc = 10:1) 
1H NMR (400 MHz, CDCl3): δ = 4.46 (1H, ddd, J = 8.5, 3.9, 3.0 Hz), 4.26 
(1H, dd, J = 9.0, 8.5 Hz), 4.19 (1H, dd, J = 9.0, 3.0 Hz), 3.78-3.68 (1H, m), 
3.65-3.58 (1H, m), 2.34 (1H, qqd, J = 7.0, 7.0, 4.0 Hz), 1.76-1.65 (1H, m), 
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1.54- 1.18 (13H, m), 1.14 (3H, d, J = 7.0 Hz), 0.93-0.85 (18H, m), 0.02 (6H, 
s)  
13C NMR (100 MHz, CDCl3): δ = 177.2, 153.7, 72.2, 63.0, 58.4, 37.5, 37.2, 
32.0, 30.0, 28.4, 25.9, 24.9, 22.6, 18.1, 18.0, 16.4, 14.7, 14.0. -4.7, -4.5  
 [α]D
23 = - 29.2 (c 1.17, MeOH) 
HRMS-ESI: m/z [M + Na]+calcd for C23H45O4NNaSi: 450.3010; found 
450.3009 
IR (ATR): 2929, 1780, 1701, 1385, 1201, 1058, 833, 772 cm-1 
Minor isomer epi-124: 
Rf value = 0.38 (n-hexane: EtOAc = 10:1) 
1H NMR (400 MHz, CDCl3): δ = 4.45 (1H, ddd, J = 8.0, 4.1, 3.0 Hz), 4.25 
(1H, dd, J = 9.0, 8.0 Hz), 4.20 (1H, dd, J = 9.0, 3.0 Hz), 3.74-3.58 (2H, m), 
2.35 (1H, qqd, J = 7.0, 7.0, 4.0 Hz), 1.82-1.71 (1H, m), 1.49-1.23 (12H, m), 
1.21 (3H, d, J = 7.0 Hz), 0.92-0.85 (18H, m), 0.03 (6H, s) 
13C NMR (100 MHz, CDCl3): δ = 177.1, 153.6, 72.0, 63.1, 58.4, 37.8, 36.7, 
34.4, 32.0, 28.4, 25.9, 25.0, 22.6, 18.1, 17.9, 14.6, 14.1, -4.5, -4.5 
[α]D
24 = - 60.4 (c 1.06, MeOH) 
HRMS-ESI: m/z [M + Na]+calcd for C23H45O4NNaSi: 450.3010; found 
450.3007 
IR (ATR): 2929, 1780, 1701, 1385, 1201, 1058, 833, 772 cm-1 
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Compound 112 
To a solution of compound 124 (230.2 mg, 0.538 mmoles) in CH2Cl2 (4.6 
mL) at -78 °C was added diisobutylaluminium hydride (DIBAL) in 1.0 M in 
hexanes (1.35 mL, 1.345 mmoles). The reaction was stirred for 30 minutes 
and then MeOH (87.1 µL, 2.152 mmoles) was added and the reaction was 
allowed to warm to room temperature. To the resulting mixture, aq. Rochelle 
salt (4.0 mL) was added and vigorously stirred until the white precipitate 
dissolved. The aqueous layer was then extracted with CH2Cl2 three times (3 × 
3.0 mL) and the combined organic layer was dried over Na2SO4 and 
concentrated. The resulting aldehyde was used without further purification. 
To a solution of the phosphonate 125 (389.3 mg, 1.399 mmoles) in THF (6.0 
mL), was added LiHMDS (1.0 M in THF, 1.24 mL, 0.1.237 mmoles) at -
78 °C. The reaction was then stirred at -25 °C for 30 minutes. A solution of 
the crude aldehyde in THF (3.0 mL) was then added to the mixture at -78 °C, 
following which the reaction temperature was again raised to -25 °C and 
stirred for 6 hours. The reaction was then quenched with aq. NH4Cl (5.0 mL), 
raised to room temperature, and the aqueous layer was extracted three times 
with EtOAc (3 × 1.0 mL). The combined organic layer was dried over 
Na2SO4, concentrated, and the residue was then purified by silica gel column 
chromatography (n-hexane: PhMe = 95:5 to 80:20) to give the compound 112 
(147.9 mg, 0.348 mmoles, 65% in 2 steps) as a colourless oil. 
Rf value = 0.43 (n-hexane: PhMe = 1:1) 
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1H NMR (400 MHz, CDCl3): δ = 7.15 (1H, dd, J = 15.1, 11.0 Hz), 6.10 (1H, 
dd, J = 15.1, 11..0 Hz), 5.95 (1H, dd, J = 15.1, 8.0 Hz), 3.63-3.56 (1H, m), 
2.25-2.14 (1H, m), 1.48 (9H, s), 1.41-1.20 (14H, m), 1.01 (3H, d, J = 7.0 Hz), 
0.88 (9H, s), 0.03 (3H,s), 0.02 (3H, s) 
13C NMR (100MHz, CDCl3): δ = 166.7, 149.5, 144.1, 126.7, 121.3, 80.0, 
72.3, 37.3, 37.0, 34.6, 32.1, 32.0, 30.3, 30.0, 29.7, 28.2, 25.9, 25.0, 22.6, 20.1, 
18.1, 14.1, -4.4 
[α]D
 23 = + 39.7 (c 1.15, MeOH) 
HRMS-ESI: m/z [M + Na]+ calcd for C25H48O3NaSi: 447.3265; found 
447.3264 
IR (KBr): 2956, 1710, 1137, 773 cm-1 
 
Compound 98 
A solution of compound 112 (89.0 mg, 0.209 mmoles) in EtOH (3.2 mL) and 
10% Pd/C (12.0 mg) was stirred under hydrogen atmosphere at room 
temperature for 3 hours. The mixture was then filtered through a pad of celite, 
and the filtrate was concentrated and the resulting residue was used without 
further purification. 
The residue was taken up in MeCN (3.0 mL) and HF•py was added dropwise 
at 0 °C. The reaction mixture was stirred at room temperature. When the 
starting material disappeared on TLC, the reaction was diluted with EtOAc 
(8.0 mL) and poured into an aqueous solution of NaHCO3 slowly at 0 °C. 
The aqueous layer was then extracted three times with EtOAc (3 × 1.2 mL) 
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and the combined organic layer was dried over Na2SO4 and concentrated. The 
residue was then purified by silica gel chromatography (n-hexane: EtOAc = 
8:1) to furnish the alcohol 98 (58.1 mg, 0.184 mmoles, 88% in 2 steps) as a 
colourless oil. 
Rf value = 0.21 (n-hexane: EtOAc = 4:1) 
1H NMR (400 MHz, CDCl3): δ = 3.61-3.51 (1H, m), 2.20 (2H, t, J = 7.6 Hz), 
1.61-1.08 (20H, m), 1.44 (9H, s), 0.89 (3H, t, J = 7.0 Hz), 0.86 (3H, d, J = 6.8 
Hz) 
13C NMR (100 MHz, CDCl3): δ = 173.3, 79.9, 72.3, 37.5, 36.6, 35.6, 34.8, 
32.7, 32.6, 31.9, 28.1, 26.5, 25.3, 22.6, 19.5, 14.1 
[α]D
26 = + 1.0 (c 1.03, MeOH) 
HRMS-ESI: m/z [M + Na]+ calcd for C19H38O3Na: 337.2713; found 
337.2712 
IR (ATR): 3358, 2928, 1731, 1151, 755 cm-1 
Comparison of chemical shifts of 1H NMR spectra of alcohol 98 between 
Tatsuta’s group and our data in CDCl3: 
 
Literature data38 Our compound 
(alcohol 98) 
3.56 (1 H) 3.61-3.51 (1 H) 
2.21 (1 H) 2.20 (1 H) 
1.44 (9 H) 1.44 (9 H) 
1.61-1.08 (20 H) 1.61-1.09 (20 H) 
0.90 (3H) 0.89 (3H) 
0.86 (3H) 0.86 (3H) 
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Compound 99 
To a solution of 92 (76.7 mg, 0.169 mmoles) and 2,4,6-trichlorobenzoyl 
chloride (54.7 µL, 0.350 mmoles) in THF (3.0 mL) at 0 °C, was added Et3N 
(117.2 µL, 0.059 mmoles) and stirred for two hours at room temperature. The 
solvent was then evaporated and the residue was taken up in PhMe (2.0 mL). 
A solution of the alcohol 98 (44.3 mg, 0.140 mmoles) in PhMe (2.0 mL + 0.5 
mL wash) and DMAP (68.4 mg, 0.56 mmoles) was then added and the 
resulting mixture was stirred at room temperature. After 6 hours, an aqueous 
solution of NaHCO3 was added at 0 °C and the aqueous layer was extracted 
three times with EtOAc (2.0 mL × 3). The combined organic layer was dried 
over Na2SO4, concentrated and purified by silica gel chromatography (PhMe: 
EtOAc = 10:1) to furnish the ester 99 (139.0 mg, 0.185 mmoles, 76%) as a 
light yellow oil. 
Rf value = 0.56 (PhMe: EtOAc = 8:1)  
1H NMR (400 MHz, CDCl3): δ = 7.14-7.05 (2H, m), 6.85-6.78 (2H, m), 4.95-
4.82 (1H, m), 4.75-4.67 (0.5H, m), 4.01-3.93 (3.5H, m), 3.28-3.16 (1H, m), 
2.95-2.85 (1H, m), 2.76 and 2.70 (3H, s), 2.20 (3H, t, J = 7.6 Hz) 1.44 (9H, s), 
1.39-1.20 (m, 18H), 0.92-0.81 (m, 12H), 0.09 (s, 6H)  
13C NMR (100 MHz, CDCl3) : δ = 173.3, 171.2, 171.0, 157.7, 157.5, 155.2, 
129.8, 129.8, 129.6, 129.5, 114.5, 114.4, 80.0, 79.9, 79.7, 75.9, 75.6, 69.3, 
69.2, 62.0, 60.8, 59.4, 36.5, 35.6, 34.4, 34.3, 34.1, 33.8, 32.6, 32.4, 32.3, 31.6, 
31.5, 30.3, 29.7, 28.3, 28.2, 28.1, 26.5, 25.9, 25.4, 22.5, 19.4, 14.0, -5.2  
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[α]D
25= - 25.8 (c 1.01, MeOH) 
HRMS-ESI: m/z [M + Na]+ calcd for C42H75O8NNaSi: 772.5154; found 
772.5148 
IR (KBr): 2924, 2853, 1733, 1701, 1458, 1250, 1219, 1146, 773 cm-1  
 
 
Compound 91 
To a solution of compound 99 (85.9 mg, 0.114 mmoles) in CH2Cl2 (4.0 mL) 
at 0 °C was added 98% TFA (1.0 mL) and stirred for 35 minutes at room 
temperature and then concentrated. The residue was then taken up in CH2Cl2 
(64.0 mL) and cooled to 0 °C. Et3N (0.19 mL, 1.368 mmoles) was added 
dropwise which was followed by the addition of BOP-Cl (174.1 mg, 0.684 
mmoles). The reaction was allowed to stir at 0 °C for 48 hours after which it 
was concentrated and aq. NaHCO3 (2.0 mL) was added. The aqueous layer 
was extracted three times with CHCl3 (4.0 mL × 2) and the combined organic 
layer was concentrated, dried over Na2SO4 and purified by silica gel 
chromatography (n-hexane: EtOAc = 5:1) to give PF1163B 91 (27.0 mg, 
0.058 mmoles) as a mixture of rotational isomers.40 
Rf value = 0.48 (n-hexane: EtOAc = 1:1) 
1H NMR (400 MHz, CDCl3): δ = 7.21-7.05 (2H, m), 6.88-6.79 (2H, m), 5.84-
5.75 (0.6H, m), 4.94-4.78 (1H, m(s-trans)), 4.60-4.54 (0.27H, m(s-cis)), 4.09-
4.01 (2H, m), 3.99-3.91 (2H, m), 3.60-3.14(4H, m), 3.04-2.90 (3H, m), 2.84-
2.61 (2H, m), 2.47-1.96 (4H, m), 1.54-1.03 (16H, m), 0.92-0.79 (6H, m)   
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13C NMR (100 MHz, CDCl3): δ = 173.4, 171.1, 170.2, 157.2, 130.2, 129.7, 
129.1, 114.9, 114.4, 75.3, 69.1, 69.0, 61.5, 55.4, 35.1, 35.0, 34.0, 33.7, 33.6, 
33.5, 31.7, 31.6, 29.4, 29.3, 28.7, 26.5, 25.0, 20.5, 14.0 
[α]D
23 = - 109.6 (c 0.49, MeOH) 
IR (KBr): 3400, 2950, 2929, 1731, 1632, 1512, 1248, 1220, 1078, 772 cm-1 
HRMS-ESI: m/z [M + Na]+ calcd for C27H43O5NNa: 484.3033; found 
484.3033. 
 
 
Synthesis of acid fragment 92 
To a solution of ester 102 (46 mg, 0.107 mmoles) in dry DMF (2.0 mL), was 
added MeI (20.0 µL, 0.321 mmoles) and NaH (5.0 mg, 0.107 mmoles) at 
0 °C. The reaction was then allowed to attain room temperature and stirred 
for 6 h until the TLC showed completion of the reaction. The mixture was 
diluted with H2O (5.0 mL) and EtOAc (1.0 mL) and the aqueous layer was 
then extracted three times. The combined organic part was dried over Na2SO4 
and concentrated. The residue was used for the next reaction without 
purification.  
The residue (47.0 mg) from methylation reaction was taken up in EtOH (1.6 
mL) and 10% Pd/C (5.0 mg, 10 mol %) was added and the reaction was 
stirred at room temperature under hydrogen atmosphere for 10 h. The mixture 
was then filtered through celite, and concentrated to give the crude free 
alcohol. The alcohol was used in the next reaction without further 
purification. 
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The crude alcohol (39.0 mg) was dissolved in CH2Cl2 (1.4 mL) and TBSCl 
(18.3 mg, 0.121 mmoles) was added followed by the addition of imidazole 
(16.0 mg, 2.0 mmoles). The reaction was stirred at room temperature for 1 h 
and upon the completion of reaction, was quenched with aq. NH4Cl (1.0 mL). 
The organic layer was then separated and the organic layer was extracted 
three times with CHCl3 (3 × 2.0 mL). The combined organic extract was 
dried over Na2SO4 and concentrated. The TBS protected alcohol was used in 
the next reaction without purification. 
The crude TBS protected alcohol (37.0 mg) was dissolved in THF (1.5 mL), 
H2O (0.5 mL) and MeOH (0.5 mL). LiOH•H2O (15.0 mg, 0.237 mmoles) 
was added and the mixture was stirred for 3h at room temperature. The 
volatiles were then removed by concentration. 6 M HCl was added to the 
residue till pH 3. The aqueous layer was then extracted three times with 
EtOAc (3 × 1.0 mL). The combined organic extract was concentrated and 
purified by silica gel chromatography (n- hexane: EtOAc = 1:3 to 1:5) to 
furnish the carboxylic acid 92 as a light yellow wax (32.0 mg, 0.070 mmoles). 
The spectroscopic data are in accordance with those of the reported 
literature.22  
1H NMR (400 MHz, CDCl3): 7.15-7.04 (2H, m), 6.87-6.79 (2H, m), 4.82-
4.70 (0.5H, m), 4.59-4.49 (0.5H, m), 4.03-3.92 (4H, m), 3.30-3.18 (1H, m), 
3.10-2.90 (1H, m), 2.74 (3H),  2.68 (3H, s), 1.40 (9H, s)  1.34 (9H, s), 0.91 
(9H, s), 0.10 (6H, s) 
13C NMR (100 MHz, CDCl3): 176.0, 175.6, 157.8, 157.7, 156.4, 155.1, 129.9, 
114.7, 114.5, 80.6, 69.3, 62.0, 61.6, 61.4, 34.4, 33.8, 33.0, 30.3, 29.7, 28.2, 
28.2, 19.2, 18.4, 14.1, -5.2 
 [α]D
28 = -34.5 (c 1.36, MeOH) 
IR (KBr): 2930, 2857, 1698, 1513, 1251, 1143, 836, 777 cm-1 
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HRMS-ESI : m/z [M + Na]+ calcd for C23H39O6NNaSi: 476.2439; found 
476.2435. 
 
(iv) Synthetic Studies on Spongidepsin 
         
  
Compound 157 
To a solution of 156 (0.656 g, 6.548 mmoles) in dry CH2Cl2 (20.0 mL), was 
added TBDPSCl (1.50 g, 5.457 mmoles) and imidazole (0.743g, 10.915 
mmoles) at 0 C to rt. The reaction was allowed to stir for 3 hours and then 
quenched with aq. NH4Cl (15.0 mL). The organic layer was extracted with 
CHCl3 three times (3 × 20.0 mL) and the combined organic layer was dried 
over Na2SO4, concentrated, and purified by silica gel chromatography (n-
hexane: EtOAc = 10:1) to give 157 (1.66 g, 6.039 mmoles) as a colourless oil 
in 90% yield.  
1H NMR (400 MHz, CDCl3): 7.70-7.65 (4H, m), 7.46-7.35 (6H, m), 5.86-
5.74(1H, m), 5.03-4.91 (2H, m), 3.70-3.64 (2H, m), 2.09-2.0 (2H, m), 1.64-
1.55 (2H, m), 1.52-1.42 (2H, m), 1.06 (9H, s) 
13C NMR (100 MHz, CDCl3):138.9, 135.6, 134.1, 129.5, 127.6, 114.3, 63.7, 
33.5, 32.0, 26.8, 25.1, 19.2 
HRMS-ESI: m/z [M + H]+ calcd for C22H31OSi: 339.2139; found 339.2133. 
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Compound 158 
To a solution of 157 (301.0 mg, 0.892 mmoles) in dry THF was added 
BH3.SMe2 (0.17 mL, 1.784 mmoles) at 0 °C. The solution was then warmed 
to room temperature and stirred for 6 h following which 30% H2O2 (2.0 mL) 
and 3 M NaOH (3.0 mL) was added at 0 °C and stirred for an additional 4 h. 
The reaction was then diluted with H2O (10.0 mL) and EtOAc (15.0 mL) and 
the aqueous layer was extracted with EtOAc three times (3 × 15 mL). The 
combined organic layer was dried over Na2SO4, concentrated, and purified by 
silica gel chromatography (n-hexane: EtOAc = 3:1) to give 158 (244.3 mg, 
0.685 mmoles) a colourless oil in 77% yield. 
1H NMR (400 MHz, CDCl3): 7.69-7.64 (4H, m), 7.45-7.35 (6H, m), 3.69-
3.59 (4H, m), 1.43-1.30 (4H, m), 1.05 (9H, s) 
13C NMR (100 MHz, CDCl3): 135.6, 134.1, 129.5, 127.6, 63.8, 63.0, 32.7, 
32.5, 26.8, 25.6, 25.4, 19.2 
HRMS-ESI: m/z [M + Na]+ calcd for C22H32O2NaSi: 379.2064; found 
379.2059. 
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Compound 159 
To a solution of oxalyl chloride (70.1 µL, 0.817 mmoles) in dry CH2Cl2 (2.0 
mL) at -78 °C was added DMSO (116.1 µL, 1.634 mmoles). The mixture was 
stirred for 30 minutes and a solution of the alcohol 158 (291.5 mg, 0.817 
mmoles) in dry CH2Cl2 (2.0 mL) was added. After stirring the reaction for 3 h 
at -78 C, Et3N (0.57 mL, 4.085 mmoles) was slowly added and the mixture 
was stirred for an additional 10 minutes following which it was raised to 
room temperature. H2O (2.0 mL) was then added and the aqueous layer 
extracted three times with CHCl3 (3 × 5 mL). The combined organic layer 
was dried over Na2SO4, concentrated and purified by silica gel 
chromatography to give the aldehyde 159 (210.1 mg, 0.592 mmoles) as a 
colourless oil in 72% yield. 
1H NMR (400 MHz, CDCl3): 9.74 (1H, t, J = 2.0 Hz), 7.70-7.65 (4H, m), 
7.46-7.36 (6H, m), 3.68 (2H, t, J = 7.0 Hz), 2.44-2.38 (2H, m), 1.67-1.55 (4H, 
m), 1.47-1.37 (2H, m), 1.07 (9H, s)   
13C NMR (100 MHz, CDCl3): 202.7, 135.5, 133.9, 129.5, 127.6, 63.5, 43.8, 
32.2, 26.8, 25.4, 21.8, 19.2 
HRMS-ESI: m/z [M + Na]+ calcd for C22H30O2NaSi: 377.1907; found 
377.1901. 
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Compound 161 
To a solution of 159 (158.6 mg, 0.447 mmoles) in PhMe (3.0 mL) was added 
PPh3=CH(Me)CO2Me (311.7 mg, 0.894 mmoles) and refluxed for 3 h. The 
reaction was then cooled to room temperature and quenched with aq. NH4Cl 
(1.0 mL). The aqueous layer was extracted twice with EtOAc (2 × 2.0 mL) 
and the combined organic layer was dried over Na2SO4, concentrated and 
purified by silica gel chromatography to give 161 (76.0 mg, 0.179 mmoles) 
as a colourless oil in 40% yield.  
1H NMR (400 MHz, CDCl3): 7.68-7.64 (4H, m), 7.45-7.34 (6H, m), 6.75 (1H, 
ddq, J = 6.9, 6.9, 1.1 Hz), 3.73 (3H, s), 3.65 (2H, t, J = 6.9 Hz), 1.82 (3H, d, J 
= 1.1Hz), 1.47-1.34 (4H, m), 1.04 (9H, s)   
13C NMR (100 MHz, CDCl3): 168.7, 142.6, 135.5, 134.0, 129.5, 127.6, 63.7, 
51.6, 32.3, 28.6, 28.3, 26.8, 25.5, 19.2, 12.4 
HRMS-ESI: m/z [M + Na]+ calcd for C26H36O3NaSi: 447.2326; found 
447.2321. 
 
 
Compound 98 
To a solution of 161 (100.0 mg, 0.235 mmoles) in THF (5.0 mL) was added 
10 M NaOH. The resulting mixture was then refluxed for 10 h after which it 
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was cooled and allowed to attain room temperature. The reaction was then 
cooled to 0 °C and neutralized with 2 N HCl until pH 3. The aqueous layer 
was then extracted three times with EtOAc (3 × 10 mL) and the combined 
organic layer was dried over Na2SO4 and concentrated to give the crude 
carboxylic acid. The acid was used in the next reaction without further 
purification. 
The crude acid (94.0 mg) was dissolved in THF (5.0 mL) and cooled to 0 C. 
Et3N (86.2 µL, 0.618 mmoles) and PivCl (32.6 µL, 0.265 mmoles) were 
added sequentially at that temperature. After stirring for 2 hours at room 
temperature, oxazolidinone (32.5 mg, 0.252 mmoles) and LiCl (15.5 mg, 
0.366 mmoles) was added. The reaction was then stirred for 12 hours and 
then concentrated. The residue was dissolved in EtOAc (5.0 mL) and 
extracted with H2O (3.0 mL). The combined organic layer was dried over 
Na2SO4, concentrated, and purified by silica gel chromatography to give 147 
(71.6 mg, 0.137 mmoles) as a colorless oil.   
1H NMR (400 MHz, CDCl3): 7.69-7.64 (4H, m), 7.45-7.34 (6H, m), 6.08 (1H, 
ddq, J = 7.0, 7.0, 1.0 Hz), 4.51 (ddd, J = 9.0, 5.5, 4.5 Hz), 4.30 (1H, dd, J = 
9.1, 9.0 Hz), 4.17 (1H, dd, J = 9.1, 4.5 Hz), 3.65 (1H, dd, J = 6.9, 6.5 Hz), 
2.36 (1H, qqd, J = 7.0, 7.0, 4.0 Hz), 2.20-2.11 (2H, m), 1.89 (3H, d, J = 1.0 
Hz), 1.44-1.38 (4H, m), 1.04 (9H, s), 0.92 (3H, d, J = 7.0 Hz), 0.90 (3H,d, J = 
7.0 Hz) 
13C NMR (100 MHz, CDCl3): 175.7, 156.6, 135.5, 134.0, 129.5, 127.6, 66.3, 
63.7, 58.2, 54.7, 51.6, 40.4, 36.1, 32.3, 28.6, 28.3, 26.8, 25.5, 21.6, 20.2, 19.2, 
17.9, 17.9, 14.5, 12.4 
 
 
 
 
96 
 
 
Compound 162 
To a solution of 147 (25.0 mg, 0.048 mmoles) in dry THF at -78 C, was 
added NaHMDS (1.0 M in THF, 81.4 µL, 0.081 mmoles) dropwise. The 
reaction was allowed to stir at the same temperature for 2 hours. A solution of 
2-methylbenzimidazole (19.0 mg, 0.144 mmoles) in dry THF (2.0 mL) was 
then cannulated and the reaction mixture was raised to room temperature. Aq. 
NH4Cl (2.0 mL) was added then and the aqueous layer was extracted with 
EtOAc three times (3 × 4.0 mL). The combined organic layer was dried over 
Na2SO4, concentrated and purified by silica gel chromatography to give 162 
(17.4 mg, 0.033 mmoles) as a colourless oil. 
1H NMR (400 MHz, CDCl3): 7.68-7.63 (4H, m), 7.45-7.34 (6H, m), 5.70-
5.61 (1H, m), 5.56-5.48 (1H, m), 4.52-4.43 (2H, m), 4.25 (1H, dd, J = 9.0, 
8.9 Hz), 4.18 (1H, dd, J = 9.0, 4.5 Hz), 3.63 (1H, dd, J = 6.9, 6.5 Hz), 2.30 
(1H, qqd, J = 7.0, 7.0, 4.0 Hz), 2.03-1.95 (2H, m), 1.46-1.38 (3H, m), 1.22 
(3H, d, J = 6.9 Hz), 1.04 (9H, s), 0.88 (3H, d, J = 7.0 Hz), 0.81 (3H, d, J = 
7.0 Hz) 
13C NMR (100 MHz, CDCl3): 175.7, 156.6, 135.5, 134.0, 129.5, 127.6, 66.3, 
63.7, 58.2, 54.7, 51.6, 40.4, 36.1, 32.3, 28.6, 28.3, 26.8, 25.5, 21.6, 20.2, 19.2, 
17.9, 17.9, 14.5, 12.4 
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Compound 149 
To a solution of bromodiethyl acetal (0.24 mL, 1.545 mmoles) in CH2Cl2 (2.0 
mL) at -78 °C, was added BF3.OEt2 (0.18 mL, 1.472 mmoles) at -78 °C. The 
solution was stirred for 15 mintues at the same temperature after which a 
solution of 26 (500 mg, 1.472 mmoles) in CH2Cl2 (2.0 mL) was cannulated. 
The temperature was then raised to 0 °C and the reaction was stirred for an 
additional 12 hours. Pyridine (0.47 mL, 5.888 mmoles) was then added and 
the reaction was warmed to room temperature after which aq. NaHCO3 (3.0 
mL) was added. The aqueous layer was extracted with CHCl3 three times (3 
× 4 mL) and the combined organic layer was dried over Na2SO4, 
concentrated and purified by silica gel chromatography to give 149 (376.8 
mg, 1.001 mmoles) as a colorless oil. 
1H NMR (CDCl3, 400 MHz): 5.76 (1H, dd, J = 9.0, 1.0 Hz), 4.52 (1H, ddd, J 
= 9.0, 5.5, 4.5 Hz), 4.32 (1H, dd, J = 9.0, 8.9 Hz), 4.17 (1H, dd, J = 9.0, 5.5 
Hz), 3.74 (1H, dq, J = 9.0, 7.0 Hz), 3.60 (2H, dd, J = 2.5, 2.0 Hz), 3.46 (1H, 
dq, J = 9.0, 7.0 Hz), 2.95-2.84 (1H, m), 2.35 (1H, qqd, J = 7.0, 7.0, 4.0 Hz), 
1.97 (3H, d, J = 1.0 Hz), 1.08 (3H, d, J = 7.0 Hz), 0.91 (6H, dd, J = 7.1, 7.0 
Hz)  
13C NMR (CDCl3, 100 MHz): 171.6, 153.6, 139.8, 131.2, 81.1, 66.1, 63.4, 
58.1, 36.5, 34.4, 28.2, 17.8, 15.3, 15.3, 15.0, 13.9 
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Compound 150 
To a solution of 149 (52.0 mg, 0.138 mmoles) in EtOH (2.0 mL) was added 
Zn dust (135.5 mg, 2.07 mmoles) and NH4Cl (73.9 mg, 1.38 mmoles) and 
stirred vigorously at 50 °C for 1 h. After TLC showed complete consumption 
of starting material, the reaction mixture was cooled to room temperature and 
filtered through a cotton plug. The filtrate was concentrated and purified by 
silica gel chromatography to give 150 (29.4 mg, 0.117 mmoles) as a colorless 
oil.  
1H NMR (CDCl3, 400 MHz): 5.86 (1H, dq, J = 8.0, 1.0 Hz), 5.78 (1H. ddd. J 
= 16.0, 10.5, 6.5 Hz), 5.14-5.07 (1H, m), 5.04-4.99 (1H, m), 4.50 (1H, ddd, J 
= 9.0, 5.5, 4.5 Hz), 4.32 (1H, dd, J = 9.0, 8.9 Hz), 4.18 (1H, dd, J = 9.0, 5.5 
Hz), 3.25-3.16 (1H, m), 2.37 (1H, qqd, J = 7.0, 7.0, 4.0 Hz), 1.93 (3H, d, J = 
1.0 Hz), 1.13 (3H, d, J = 7.0 Hz), 0.91 (6H, dd, J = 7.1, 7.0 Hz) 
13C NMR (CDCl3, 100 MHz): 171.8, 153.5, 141.3, 140.3, 130.3, 113.9, 63.3, 
58.2, 36.4, 28.1, 19.5, 17.8, 14.9, 13.7 
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Compound 151 
To a solution of 150 (19.3 mg, 0.076 mmoles) in dry THF (1.0 mL) and liq. 
NH3 (4.0 mL) at -78 °C, was added lithium in small pieces (1.6 mg, 0.228 
mmoles). The dark blue solution was stirred at the same temperature for 6 
minutes after which a solution of 2-isopropylbenzimidazole (60.9 mg, 0.38 
mmoles) in dry THF (2.5 mL) was cannulated into the reaction mixture. 
NH4Cl was then added (28.7 mg, 0.532 mmoles) and the mixture was 
allowed to attain room temperature to evaporate NH3. After about 2 hours, 
the reaction mixture was concentrated and diluted with EtOAc (3.0 mL) and 
H2O (1.5 mL). The aqueous layer was extracted three times with EtOAc (3 × 
3.0 mL). The combined organic layer was dried over Na2SO4, concentrated 
and purified by silica gel chromatography to give 151 (12.4 mg, 0.048 
mmoles) as a colorless oil.  
1H NMR (CDCl3, 400 MHz): 5.70 (1H, ddd, J = 17.5, 10.1, 8.0 Hz), 5.03-
4.91 (2H, m), 4.44 (1H, ddd, J = 9.0, 4.5, 4.0 Hz), 4.25 (1H, dd, J = 9.0, 8.5 
Hz), 4.19 (1H, dd, J = 9.0, 3.1 Hz), 3.85-3.75 (1H, m), 2.35 (1H, qqd, J = 7.0, 
7.0, 4.0 Hz), 2.26-2.16 (1H, m), 1.88-1.79 (1H, m), 1.37-1.30 (1H, m), 1.12 
(3H, d, J = 6.9 Hz), 1.01 (3H, d, J = 7.0 Hz), 0.91 (3H, d, J = 7.1 Hz), 0.87 
(3H, d, J = 7.0 Hz) 
13C NMR (CDCl3, 100 MHz): 177.4, 153.6, 143.6, 113.3, 63.0, 58.4, 40.3, 
36.2, 35.8, 28.3, 20.8, 18.0, 16.8, 14.6 
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Compound 134 
To a solution of 151 (10.0 mg, 0.039 mmoles) in THF/H2O (4.0 mL, 1:1 
ratio) at room temperature was added LiOH•H2O (5.0 mg, 0.117 mmoles) 
and 30% H2O2 (8.8 µL, 0.039 mmoles). The reaction was stirred for 3 hours 
at room temperature and then 2 N HCl was added till pH 3. The aqueous 
layer was then extracted with EtOAc three times (3 × 4.0 mL). The combined 
organic layer was dried over Na2SO4, concnentrated and purified over silica 
gel chromatography to give the acid 134 (3.90 mg, 0.027 mmoles) as a 
colorless wax. 
1H NMR (CDCl3, 400 MHz): 5.68-5.57 (1H, m), 5.03-4.93 (2H, m), 2.55-
2.48 (1H, m), 2.24-2.18(1H, m), 1.79-1.70 (1H, m), 1.40-1.36 (1H, m), 1.18 
(3H, d, J = 7.0 Hz), 1.12 (3H, d, J = 7.0 Hz)  
13C NMR (CDCl3, 100 MHz): 183.0, 143.6, 113.9, 40.2, 37.6, 36.1, 20.9, 
16.9 
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